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Abstract 
Early detection and treatment of diseases has the potential to dramatically improve 
patient outcomes. Diseases like cancer have shown remarkably higher survival rates when the 
cancer is detected early, before it has had a chance to metastasize and migrate to different 
regions. One way to increase rates of early detection is to implement annual screenings.  
Current screening methods often focus on blood tests, which gather molecular 
information from the circulation, or imaging, which provides anatomical details. Molecular 
imaging has the ability to provide both types of information, but the high cost and radiation risk 
often preclude its use in population screening. In this thesis, we hypothesized that near-infrared 
fluorescent imaging agents could be administered orally and yield sufficient contrast for disease 
diagnosis. The use of NIR fluorescent targeting ligands provides both spatial and molecular 
information while making the entire process fast, inexpensive, completely non-invasive, and safe 
with the use of non-ionizing radiation.  
 For proof-of-concept studies to develop this novel technique, we selected integrin of the 
form αvβ3 as the target, and a high affinity peptidomimetic as the ligand. The major challenge of 
developing an orally available imaging agent is that orally available drugs and imaging agents 
generally have disparate properties. Orally available drugs are typically small in size and 
lipophilic in nature, while imaging agents tend to be larger in size and hydrophilic. In spite of 
these challenges, an IRDye800CW-labeled agent had an oral absorption of 2.3% and was 
selected for studies in the detection of two diseases: breast cancer and rheumatoid arthritis.  
xii		
 Mammography uses x-rays to detect suspicious lesions when screening for breast cancer 
but only provides anatomical data. This has lead to high false positive rates, unnecessary follow 
up tests and an estimated $4 billion in expenditure due to overdiagnosis. The method in this 
dissertation has the potential to increase sensitivity and specificity to improve early diagnoses 
and patient outcomes. The IRDye800CW agent was dosed at 5 mg/kg in an orthotopic tumor 
xenograft mouse model. Live animal imaging at 6, 24 and 48 hours post administration showed 
the highest target to background ratio of ~4 at 48 hours and histology showed high uptake of the 
agent by macrophages and breast cancer cells. Negligible uptake of a low affinity imaging agent 
control demonstrated specific uptake of the IRDye800CW agent in the tumor.  
 Rheumatoid arthritis (RA) is an autoimmune disease that leads to largely irreversible 
joint damage over time, but effective treatments are available. Therefore, there is intense interest 
in early detection of RA to prevent further damage, and some studies have even indicated that 
the disease could be cured (no long-term treatment required) if detected early. However, current 
methods lack the sensitivity to detect RA at an early stage. Oral delivery of the IRDye800CW 
agent in a collagen antibody induced arthritis mouse model showed significantly higher uptake in 
the inflamed joints compared to healthy joints. To scale the expected signal to clinically relevant 
depths, we developed a 3D COMSOL model for optical simulations of RA detection in the 
human hand. The simulations showed that for target to background concentration ratios of the 
imaging agent of 5.5 and 6.5, there was 95% and 98% probability of detection of the inflamed 
joint. The in vivo mouse model had an estimated target to background concentration ratio of ~20, 
which makes the detection of RA in humans very promising.  
 This dissertation demonstrates the oral delivery of molecular imaging agents for the 
detection of breast cancer and RA in relevant mouse models. These studies provide the 
xiii		
foundation to develop a range of oral molecular imaging agents for other biomarkers and 
diseases with the potential for earlier diagnosis and intervention to improve patient outcomes.
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Chapter 1: Introduction 
1.1 Background 
It is widely accepted that the early detection of diseases can have a significant impact on 
patient outcomes. This is evident in diseases from infectious disease to cancer. Early intervention 
can prevent spreading of the disease or pathogen and stop irreversible damage. For example, in 
the case of a disease like breast cancer when it is diagnosed early and has not metastasized, the 
5-year survival rates are over 90% whereas they drop to about 20% for cancers that have spread 
from the primary site1. For many diseases, a common screening method is to test the blood of the 
patient for biomarkers that would indicate the onset of a disease. This technique gives no spatial 
information about the origin of the biomarker/site of disease and requires high sensitivity to 
identify specific biomarkers out of all the molecules present in blood. The lack of spatial 
information and the need for early detection has led to a noteworthy push by the medical/ 
pharmaceutical community to develop techniques that can help diagnose diseases non-invasively 
while they are still in their early stages. 
Historically, diseases were often diagnosed when the symptoms became apparent, which 
changed with the introduction of the imaging modalities for detection. With the discovery of X-
ray in 1895, the field of medical imaging has steadily grown over time. X-rays, a form of 
ionizing electromagnetic radiation that can penetrate layers of opaque materials, allowed medical 
personnel to identify any injuries or abnormalities, particularly in bones. The use of heavy 
elements, such as iodine and barium as contrast agents improved the imaging of soft tissues. X-
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ray tomography—replaced by computed tomography (CT) scans in the 1970s—was introduced 
in the 1940s and was used to obtain multiple image slices of the tissue by rotating the X-ray 
tube2. It was around this same time that the negative impacts of high amounts of radiation came 
to light, which has resulted in work to reduce radiation doses3. The 1950s saw the rise of nuclear 
medicine with the use of radioactive compounds instead of X-ray tubes and the advent of 
positron emission tomography (PET) scanning2 and single photon emission computed 
tomography (SPECT) in the 1970s4. Ultrasound, first used in the 1970s, was one of the first 
imaging modalities that did not use any ionizing radiation and employed high frequency sound 
waves to generate images of the muscles, tendons, organs and fetuses inside the body. Magnetic 
resonance imaging (MRI) also emerged during this time period. It uses strong magnetic fields 
and radio waves to create anatomical images of the internal organs. The 1960s and 70s also saw 
the use of fluorescence to view hemorrhages and abnormalities in the eye5 with recent uses of 
tissue autofluorescence in detection of diseases like oral neoplasia6. Fluorescence is the emission 
of non-ionizing electromagnetic radiation in the visible or near infrared range that is emitted by a 
molecule after excitation, usually with a form of radiation with a shorter wavelength.     
 These imaging modalities have improved over time with the technological boom of the 
last few decades. With an improvement in the technology itself, there has been a push for these 
imaging modalities to be able to provide more information with the use of imaging agents or 
contrast agents. Some well known imaging agents are gadolinium for MRI, 18F-
fluorodeoxyglucose for PET and iodine and barium for X-rays. These imaging agents help 
provide more information about internal organs and physiological processes in the body. Of the 
current FDA approved imaging agents, sixty-three were identified for Scintigraphy, 27 for X-ray, 
13 for MRI, 8 for PET, 3 for Ultrasound and 3 for Optical (Fluorescent) imaging7.  
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However, in order to get more detailed information about disease progression and 
monitoring therapeutic responses there needs to be improved specificity when using these 
imaging modalities8. Molecular imaging agents can provide this. Compared to contrast agents 
that are non-specific in nature and typically a reflection of the local physiology (e.g. blood flow, 
interstitial volume, etc.), molecular imaging agents interact specifically with a biomarker and are 
able to provide molecular information about the disease itself. With the medical community 
pursuing precision medicine, there is an increased need for molecular imaging agents to provide 
information in a non-invasive manner.  
 The aim of this thesis was to develop a screening method using a molecular imaging 
agent for the early detection of disease. In order to design a system that is inexpensive, safe, and 
easy to implement (for patient compliance), we had to select an imaging modality and route of 
administration of the imaging agent that would fit these criteria to make it feasible for screening 
large portions of the population.  	
1.2 Methods of Detection 
The criteria considered for selecting an imaging modality were safety, cost, ability to 
provide molecular contrast, non-invasive nature of the method, and depth of imaging. Safety is 
paramount for a screening method since even a small risk percentage is amplified across 
thousands of (presumably healthy) people. For reference, there were about 40 million 
mammograms (MQSA national statistics) in the USA and a 0.01% risk would result in roughly 
4000 people dealing with an adverse effect. Because of the large number of people likely to 
partake in screenings, cost is a major factor that needs to be considered. The imaging modality 
and imaging agents need to be relatively inexpensive when annual screenings are being 
considered. The 3rd criterion was molecular information. Anatomical data from medical imaging 
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can lead to several false positives, further testing and increased expenditure (see Chapter 4.3). A 
molecular imaging agent that can provide molecular information about the disease can help 
mitigate some of the false positives and extra expenditure as the imaging agent interacts with a 
biomarker specific to the disease. With the large populations being screened a non-invasive 
technique would be ideal to increase patient compliance (see Chapter 3.3). Finally, the imaging 
modality should have a sufficient depth of imaging to provide accurate information when 
imaging at clinically relevant depths.  
Keeping the above-mentioned criteria in mind, all the imaging modalities were compared 
against each other with the summarized results in Table 1.1. CT is a form of X-ray imaging that 
images several sections (tomography) to represent the acquired data in a three-dimensional 
format. CT is a relatively fast imaging process, has a spatial resolution of about ~0.5 to 1 mm, is 
moderately expensive, has a high depth of imaging and is non-invasive9. Some of the limitations 
of this imaging modality are exposure to ionizing radiation, the use of contrast agents that can 
have renal toxicity, and negligible molecular contrast. MRI is a technique that uses magnetic 
fields and radio waves to form a detailed image of the entire body. MRI takes longer than a CT 
to complete a scan, has a spatial resolution of ~1mm, is expensive, has a high depth of imaging, 
is non-invasive and uses non-ionizing radiation. While MRI has excellent soft-tissue resolution, 
the sensitivity to exogenous imaging agents is low (albeit better than CT). PET is an imaging 
technique that uses radiolabeled imaging agents that decay and release positrons. PET detects the 
gamma ray pairs that are formed when the positron strikes an electron and uses this information 
to build tomographic images. SPECT on the other hand uses radiolabels that emit gamma rays 
that are captured by a gamma camera to create a 3D image of the distribution of the imaging 
agent. PET and SPECT have a spatial resolution of 5-7 mm and 8-10 mm, respectively10. PET is 
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an expensive imaging technique, whereas SPECT is comparatively moderately expensive10. Both 
imaging modalities have a high depth of imaging, high molecular contrast and high sensitivity. 
However, they are invasive as the molecular imaging agent is injected intravenously, and use 
ionizing radiation. Ultrasound employs high frequency sound waves to produce a two-
dimensional anatomical image based on the how the waves travel through different tissues. 
Ultrasound has a spatial resolution of 0.1mm or 1-2 mm depending on the depth10. The technique 
is cheap, safe (lacks ionizing radiation), and some molecular imaging is possible with the use of 
microbubbles and vascular targeting. However, microbubbles require intravenous delivery. 
Therefore, this method generally lacks molecular contrast and has a limited depth of imaging in 
certain organs. Fluorescence imaging has a spatial resolution of 2-3 mm10 for tomography and 
can have resolution of microns for surface imaging. It is relatively cheap, uses non-ionizing 
radiation, and has high sensitivity and molecular contrast. A major limitation of this technique is 
the low depth of imaging and the fact that it is invasive, as the fluorescent probes are typically 
injected intravenously.  
Table 1.1 Comparison of FDA Approved Imaging Modalities 
 CT PET/ SPECT X-Ray MRI Ultrasound Fluorescence 
Low Risk 
(Non-
ionizing 
Radiation) 
   ✔  ✔  ✔  
Inexpensive   ✔   ✔  ✔  
Molecular 
Contrast  ✔     ✔  
Non-
Invasive   ✔  ✔  ✔   
Depth of 
Imaging ✔  ✔  ✔  ✔  ✔   
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 With safety, cost, and the ability to provide molecular contrast being the most important 
for a screening method, fluorescence was chosen as the ideal method of detection for this thesis. 
The three optical (fluorescent) imaging agents that have been FDA approved are indocyanine 
green, fluorescein and aminolevulinic acid hydrochloride, and all are delivered intravenously 
with the aminolevulinic acid hydrochloride having the option of topical and oral delivery. 
Indocyanine green is being used to measure cardiac output11, hepatic function, liver blood flow12 
and for ophthalmic angiographies. Fluorescein, discontinued by the manufacturer, was approved 
for angiography of the retina and iris vasculature13. Aminolevulinic acid hydrochloride is a 
prodrug that is metabolized to form a fluorescent metabolite and has recently been approved as 
an intraoperative imaging agent for the visualization of malignant gliomas14.  	
1.3 Route of Administration 
As mentioned above, the fluorescence imaging agents are typically delivered intravenously, 
but in order to make the process more feasible for large scale screening methods two other routes 
of administration, subcutaneous (SC) and oral delivery, were considered. SC delivery is the 
injection of a bolus dose of a drug or imaging agent in the subcutaneous layer between the 
dermis and muscle. The drug or imaging agent is then slowly absorbed over time into the blood 
stream. This route of delivery is considered minimally invasive. Oral delivery is the consumption 
of a pill, capsule, or solution, which dissolves in the stomach, is absorbed through the intestinal 
wall, passes through the liver and enters circulation. This method is completely non-invasive. 
Oral delivery is generally preferred to SC or intravenous delivery (See Chapter 3.3) due to the 
ease of delivery, low to no chance of an allergic reaction and cheaper costs of the drugs or 
imaging agents. SC is preferred over intravenous delivery because patients can administer it 
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themselves with minimal training, whereas intravenous delivery will always require a medical 
professional for administration.  	
1.4 Depth of Imaging 
Another issue with fluorescence as the method of detection was the low depth of 
imaging. One way to rectify this is to use fluorescence with excitation and emission maxima 
closer to the infrared range. The wavelength range from 650 – 900 nm is usually referred to as 
near-infrared fluorescence (NIRF)15. NIRF increases the depth of imaging to about 1-2 cm from 
the surface of the skin. Aside from increasing the depth of penetration, another advantage of 
NIRF is that biological tissue has low absorption in this wavelength range15, thereby reducing 
autofluorescence from tissue and increasing target to background ratios16,17. FDA approved 
Indocyanine green is a non-specific NIRF imaging agent and has been shown to work well in 
humans for its intended purposes. NIRF has also shown to be successfully used in angiograms of 
the eye16, imaging the brain16, intraoperative tumor imaging18, hepatic output12 and colon polyp 
identifications19 among several others. 	
1.5 Objective 
The objective of this thesis was to develop a non-invasive screening method for the 
detection of diseases with the ability to obtain spatial and molecular information simultaneously. 
Employing oral delivery in this technique makes the process completely non-invasive and the 
use of NIRF makes the process safe with the use of an imaging modality that does not rely on 
ionizing radiation. The only limitation of this technique would be that we are limited to the 
detection of diseases within several millimeters of tissue for epifluorescence imaging or several 
centimeters when employing NIR tomography (as in breast imaging). This thesis will be a proof-
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of-concept study to show that detection of diseases post oral delivery is viable in mouse models 
with future studies looking into early detection. 	
1.6 Hypothesis 
There is no literature evidence of orally available molecular imaging agents, largely due 
to the significant differences between high oral availability and specific targeting. High oral 
bioavailability generally requires low molecular weights and high lipophilicity based on 
Lipinski’s rule of five20. Specific targeting on the other hand requires higher molecular weights 
for increased surface area to interact with the target and low lipophilicity to avoid off-site 
sticking. Despite these challenges we hypothesized that sufficient oral absorption and targeting 
could be achieved with appropriately balanced physicochemical properties of the imaging agents. 
 
1.7 Work Plan 
In order to accomplish the objective, the work plan shown in figure 1.1 was devised to 
make sure that we could develop the imaging agent and apply it to show the feasibility of 
detection of diseases in mouse models.  
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Figure 1.1 Work plan for the dissertation 
 
Chapter 2 will show the in vivo validation of a theoretical computational model that can 
predict drug delivery in tumors. The model was validated in tumor xenografts in mice for wide 
range of drugs from small molecules to antibodies. The model was used to simulate the 
pharmacokinetic properties of potential imaging agents. 
Chapter 3 highlights the synthesis of the potential imaging agents and in vitro studies 
used to determine the pharmacokinetic properties of these agents. The studies were used to select 
the imaging agents that would be used in the mouse models.  
Chapter 4 uses the selected imaging agent for the detection of breast cancer in an 
orthotopic tumor xenografts mouse model.  
Chapter 5 applies the same selected imaging agents in the detection of rheumatoid 
arthritis in a Collagen Antibody Induced Arthritis (CAIA) model and uses a 3D COMSOL model 
to show that epifluorescence imaging is feasible at clinically relevant depths.   
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Chapter 2: Multichannel Imaging to Quantify Four Classes 
of Pharmacokinetic Distribution in Tumors 
	
2.1 Publication Information 
Bhatnagar S, Deschenes E, Liao J, Cilliers C, Thurber GM 2014. Multichannel Imaging to 
Quantify Four Classes of Pharmacokinetic Distribution in Tumors. Journal of pharmaceutical 
sciences  103(10):3276-3286. 
Modifications have been made to the published document to adapt the content to this 
dissertation. 
2.2 Abstract 
Low and heterogeneous delivery of drugs and imaging agents to tumors leads to 
decreased efficacy and poor imaging results. Systemic delivery involves a complex interplay of 
drug properties and physiological factors, and heterogeneity in the tumor microenvironment 
makes predicting and overcoming these limitations exceptionally difficult. Theoretical models 
have indicated there are four different classes of pharmacokinetic behavior in tissue depending 
on the fundamental steps in distribution. In order to study these limiting behaviors, we used 
multichannel fluorescence microscopy and stitching of high-resolution images to examine the 
distribution of four agents in the same tumor microenvironment. A generic partial differential 
equation model with a graphical user interface was used to select fluorescent agents exhibiting 
11		
four classes of behavior, and the imaging results compared favorably with predictions. A small 
molecule exhibited higher concentrations in regions with high blood flow, an antibody gave 
perivascular distribution limited by permeability, high plasma protein and target binding resulted 
in diffusion limited distribution for a lipophilic small molecule, and an imaging agent was 
limited by the number of binding sites in the tissue. Together, the probes and simulations can be 
used to investigate distribution in other tumor models and in designing and interpreting in vivo 
experiments. 
 
2.3 Background 
Drug delivery and distribution in tumors is a complicated interplay of local tumor 
physiology and drug properties. Understanding and being able to predict this distribution is 
imperative to developing new therapies, since poor uptake has been shown in the clinic21 to 
correlate with poor outcomes. Tumor physiology is highly variable with gradients in oxygen22, 
metabolic waste products23, pH24, differences in extracellular matrix composition25,26, cell 
packing27, interstitial pressure28, multiple cell types29, poor blood flow30, increased and variable 
permeability31, and heterogeneous target concentrations32 among others. For drug properties, the 
dose, molecular weight, charge, target affinity and specificity, shape (e.g. globular versus linear 
macromolecules33,34 or aspect ratio in nanoparticles35), surface chemistry (e.g. nanoparticles and 
antibody drug conjugates36), lipophilicity, pKa, local metabolism (e.g. antibody internalization), 
and systemic (plasma) clearance impact distribution. Even more complicated is that these effects 
are not independent. Increasing dose may have little effect if a growth receptor is saturated37, for 
example, but have a major impact in another tumor or adjacent region with much higher receptor 
concentration where many receptors remain untargeted. 
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Tumor distribution is equally important for imaging agent development. Molecular 
imaging agents like radiolabeled ligands or protease sensors38 must reach their target to bind or 
activate. The physiochemical properties of the agent must allow the binding or activation to 
dominate distribution; otherwise non-specific mechanisms such as membrane uptake may dictate 
the signal39. The requirements are even higher for quantitative imaging agents. Here, even if 
some of the target is exposed to the imaging agent, the resulting image may not be correlated 
with the amount of target40-44. In many cases, the imaging time will have an impact on the signal 
such as FDG that is limited by blood flow at early times45 and glucose uptake and metabolism at 
later times46. 
Due to the complex interplay of factors determining distribution, often multiple animal 
experiments are conducted with a variety of agents and variable results. This method is time 
consuming and expensive, with no guarantee that the models used will mimic the clinical 
scenario. Mathematical simulations are playing a larger role in determining local distribution47, 
and predictive physiologically based pharmacokinetic (PBPK) models are increasingly able to 
determine the organ level distribution for small molecules48-50 and biologics51,52. However, 
assumptions that are valid in healthy tissue may fail in the tumor microenvironment. We have 
developed partial differential equation (PDE) models to accurately describe the distribution of 
molecules in tumors47,53.  
Theoretical studies by Thurber et al indicate that there are four major classes of 
pharmacokinetic distribution in tumors depending on the rate limiting step in uptake53. 
Molecules can be classified by 1) blood flow limitations, 2) extravasation limitations, 3) 
diffusion limitations, or 4) local binding and/or metabolism limitations as shown in figure 2.1. 
These classes are useful because they allow predictions about the impact of tumor physiology on 
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distribution. For example, changes in macromolecular permeability would have no direct impact 
on a blood flow limited agent but a major change in an extravasation-limited agent.  
	
Figure 2.1 Schematic of the Krogh Cylinder Model. 
(Left) Schematic of the Krogh Cylinder Model with radial (R) and axial gradients (Z). (Right) 
Zoomed in section shows the four classes of pharmacokinetic distribution (I) blood flow limited, 
(II) extravasation limited, (III) diffusion limited and (IV) local binding/ metabolism limited.  
    
This study used multichannel imaging within the same tumor to look at different patterns 
of distribution. The variability within and between tumors makes it difficult to parse out the 
impact of drug properties versus the local microenvironment. Using multichannel imaging, 
several drugs and imaging agents were examined simultaneously in the same tumor to mitigate 
tumor microenvironment effects. The PDE model was used to predict the distribution of four 
molecules that displayed characteristics of the different classes of pharmacokinetic distribution. 
The selection criteria also ensured that these agents had different fluorescence excitation and 
emission profiles so they could be independently followed within a tumor. The model was also 
used to determine the imaging time after injection, and image analysis was used to compare the 
distribution with predictions.  
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2.4 Results 
The drugs and imaging agents used in this study are listed in table 2.1 along with their 
properties. These were injected in nude mice with A-431 xenografts, where the vasculature is 
highly heterogeneous with some hyper-vascularized areas and other necrotic regions, replicating 
the variable tumor physiology seen in many animal models and the clinic. 
 
Table 2.1 Physicochemical and optical properties of drugs and imaging agents. 
 Target Molecular Weight (Da) 
Excitation / 
Emission 
(nm) 
Plasma 
Protein 
Binding 
(%) ± S.D. 
Plasma 
Clearance 
(Alpha fraction, 
Alpha half-life, 
Beta half-life) 
 Bodipy FL - 292 502 / 511 89.7 ± 3.8 
56.2% alpha 
2.6 min 
30.37 min 
Cetuximab + 
AF 750 EGFR ~153,000 752 / 780 NA 
58% alpha 
3.0 hrs 
70.3 hrs 
Hoechst 
33342 DNA 452 352 / 455 99.3 ± 0.4 
99.5% alpha 
2 min 
1 hr 
Hoechst 
33258 DNA 424 352 / 455 98.8 ± 0.9 
98.7% alpha 
1.3 min 
3.0 hrs 
Integrisense 
680 
Integrin 
(αVβ3) 
1432 675 / 693 94.9 ± 2.3 
92.3% alpha 
6 min 
3.5 hrs 
 
BODIPY-FL was chosen as a representative blood flow limited molecule due to its low 
molecular weight and relatively low plasma protein binding for a fluorophore. This agent clears 
quickly from the blood and does not bind to a specific target, so the agent was injected 2 min 
before excising the tumor to capture differences in blood flow. The BODIPY-FL dose distributed 
in a 1.4 mL plasma volume would give an initial concentration of 35 µM, but the measured 
concentration at 1 min was closer to 5 µM. This indicates that significant redistribution occurred 
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during the first minute between the tail vein injection and retro-orbital blood sample. Cetuximab 
is a chimeric monoclonal antibody used in the clinic to treat colon54 and head and neck cancer55; 
it was selected as a representative antibody, which are generally limited by extravasation56 due to 
their large size. The high EGFR expression in this line was predicted to give extravasation 
limited uptake at this dose of Cetuximab. Hoechst 33258 was initially discovered and developed 
as an anti-parasitic drug57, but both Hoechst dyes were quickly adopted for fluorescence imaging 
given their cell permeability and bright nuclear signal. Hoechst 33342 has been used in tumors to 
track functional vessels58,59. Its high plasma protein binding ‘buffers’ the concentration within 
vessels so it is not depleted along the length of a tumor vessel. High cell uptake also allows it to 
quickly diffuse through endothelial cells, and the large number of DNA binding sites prevents it 
from saturating its target. Therefore, predictions show this agent to be limited by diffusion in the 
tissue. Hoechst 33258 has similar properties but is not taken up into cells nearly as fast as 
Hoechst 33342 even though they differ by only a hydroxyl versus an ethoxy group (Fig 2.2). 
Integrisense was originally developed as an αvβ3 integrin inhibitor for osteoporosis60. High 
specificity and affinity for its target made it an excellent imaging agent after conjugation to a 
fluorophore61. The low expression of αvβ3 in the tumor type ensured that the dose of Integrisense 
would be saturating making it binding/ metabolism limited.  
 
Figure 2.2 Structures of the Hoechst molecules.  
The difference between the two molecules is the ethoxy group vs the hydroxyl group in the 
bottom right of the structures. The predicted logP of the two molecules is 4.67 and 4.07, 
respectively.   
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 The full Krogh cylinder model simulates individual vessels within a tumor with gradients 
around the vessel (radial direction) and along the length of the vessel (axial direction) (Fig 2.1). 
In a tumor, slow blood flow depletes small molecules along the length of the vessel as seen with 
BODIPY-FL. The small size (< 300 Da) and moderate lipophilicity (predicted logP = 3) causes 
the molecule to distribute quickly in the radial direction. However, the local plasma 
concentration is quickly depleted resulting in low uptake. This is in contrast to liver tissue. Here, 
a much higher blood flow reduces depletion along the length of the vessel giving much higher 
uptake. Antibodies such as cetuximab-AF750 have a permeability that is several orders of 
magnitude lower than small molecules, so the slow rate of extravasation does not deplete the 
concentration along the length of the vessel. Extravasation limits uptake, and the molecules that 
do reach the tissue quickly bind their target and are immobilized. This results in a perivascular 
distribution (Fig 2.3). Hoechst 33342 also lacks a significant gradient along the length of the 
blood vessel. Although this is a small molecule like BODIPY-FL, it has much higher plasma 
protein binding. Binding to albumin and other proteins occurs on the millisecond time scale62, so 
as free drug extravasates, bound drug dissociates from proteins to replace it. Although 89.7% 
versus 99.3% does not appear to be a large difference, it is the free drug that matters, so the ratio 
of free drug (10.3% versus 00.7%) results in ~15 fold more free drug for BODIPY-FL. Like 
Cetuximab, the large number of DNA binding sites per cell quickly immobilizes Hoechst 33342 
before it diffuses deep in the tissue, resulting in a perivascular distribution. Finally, Integrisense-
680 lacks both radial and axial gradients since it saturates its receptor. In the simulation, a 
constant receptor concentration is assumed. The large dose of Integrisense relative to the low 
αvβ3 expression in A-431 cells saturates the receptor within 30 minutes. The simulations for the 
other agents are shown at the time of tumor excision (2 min for BODIPY-FL, 24 hours for 
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Cetuximab, and 3 hours for Hoechst 33342), but it is shown at saturation after 30 min for 
Integrisense. At longer times, this agent is internalized and trapped while it clears from the 
background. 
           	
Figure 2.3 Simulations based on Krogh Cylinder Model. 
The simulations show the concentrations of the drugs and imaging agent along the axial and 
radial gradients along with their predicted class of delivery in parentheses.  
 
 Macroscopic (stitched) images of the entire tumor were used to reconstruct the 
distribution of all four agents throughout the whole tumor (Fig 2.4). The BODIPY-FL signal is 
8.6 times higher in the liver than the tumor (p < 0.0001). This is consistent with the model 
predictions where much higher blood flow rates occur in the liver51. Cetuximab demonstrates a 
perivascular distribution in the tumor and no detectable signal in muscle that lacks human EGFR. 
Hoechst 33342 also exhibits a perivascular distribution within the tumor and labels nuclei in the 
surrounding muscle. Integrisense 680 shows a more uniform signal throughout the tumor, 
although it is higher in areas composed of macrophages and lower but detectable on tumor cells. 
CD31 labeling of the slide with an AlexaFluor-555 labeled antibody shows vasculature 
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throughout the tumor and surrounding muscle. The signal in all images was higher than 
autofluorescence. 
 
Figure 2.4 High resolution multichannel fluorescence images. 
High-resolution images were stitched together to generate a whole tumor image with the class of 
delivery shown in parentheses. The CD31 ex-vivo stain label blood vessels in the tissue slice. 
The negative merged image is of a tumor slice with no drugs or imaging agents injected and 
window leveled identically to the other imager images in the figure. The yellow doted box is 
zoomed in in figure 2.5. Scale bar = 1000 µm.  
 
 Zooming in from the whole tumor to individual vessels, the local heterogeneity is more 
apparent (Fig. 2.5). BODIPY-FL cannot be detected easily since it has low tumor uptake and 
rapidly distributes, resulting in diffuse signal. Both Cetuximab and Hoechst 33342 show large 
gradients in signal around the vessels, with few but distinct examples of mismatch: both Hoechst 
33342 signal without Cetuximab (yellow arrow) and Cetuximab signal without Hoechst 33342 
(data not shown). Integrisense-680 shows a more diffuse fluorescence consistent with saturating 
binding sites. 
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Figure 2.5 Cellular level images corresponding to the boxes in Fig. 2.4.  
The yellow arrows point to a vessel, which causes prominent Hoechst 33342 staining but no 
apparent Cetuximab staining. Perivascular Cetuximab signal was seen only after increasing the 
contrast. 
 
 Hoechst 33342 uptake into cells is rapid, staining nuclei in seconds to minutes. Hoechst 
33258, however, takes much longer to enter cells63. The nuclei reached saturation within 15 min 
with Hoechst 33342 but required over 2 hours in Hoechst 33258. Rapid cell uptake is predicted 
to quickly immobilize Hoechst 33342 near vessels, which can be seen at the macroscopic and 
cellular level (Fig 2.6). The slower cell uptake of Hoechst 33258 is predicted to yield a more 
homogeneous distribution as the drug diffuses farther into the tissue before entering cells and 
binding DNA. The overall tumor distribution and vessel level images capture this more uniform 
labeling, although the absolute signal intensity is much lower for Hoechst 33258 than Hoechst 
33342. 
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Figure 2.6 In vivo distribution and simulations for both Hoechst molecules. 
Images and simulations for Hoechst 33342 (top row) and Hoechst 33258 (bottom row). (Left) 
Macroscopic whole tumor images, (center) higher resolution images and (right) radial plots 
predicting uptake for both molecules.  
 
 Integrisense-680 has a more uniform but faint distribution throughout the tumor. In 
regions primarily consisting of A-431 cells, it has a reasonably high correlation coefficient with 
ex vivo anti-αvβ3 labeling (Fig. 2.7). However, there is also a significant signal in tumor 
macrophages. Based on estimates of pinocytosis in macrophages64, the signal in macrophages 
from fluid phase uptake is ~70% higher than the low αvβ3-expression A-431 cells. In addition, 
the Integrisense can bind to integrins on the macrophages. 
 The Cetuximab staining shows a perivascular pattern when targeted in vivo (Fig 2.7). Ex 
vivo labeling of the slide with a non-competitive antibody shows significantly more EGFR 
farther from the vessels that was not targeted by the probe. The resulting Pearson correlation 
coefficient is lower as a result.  
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Figure 2.7. Ex vivo and in vivo stains for αvβ3 and EGFR. 
Tumor sections were labeled ex-vivo with anti-αvβ3 (top middle) or anti-EGFR (bottom middle) 
AlexaFluor 555 antibody and compared to the in vivo signal (left). The Pearson correlation 
coefficient was high (0.63) for Integrisense 680 and lower (0.33) for cetuximab in agreement 
with predictions. 
2.5 Discussion 
Drug distribution in tumors is difficult to study due to the heterogeneity in the 
physiology/tumor microenvironment combined with the effects of drug properties. The 
variability includes both intra- and inter-tumor tissue heterogeneity as well as temporal changes. 
To parse out the effect of drug properties on tumoral distribution, we used multi-channel imaging 
within the same tumor to study the distribution of four different agents in the same tumor 
microenvironment. The imaging was paired with partial differential equation simulations of these 
agents to compare the theoretical distribution with the experimental results. Overall, there was 
excellent agreement with the theoretical predictions for all 5 simulated agents that varied in 
molecular weight, target specificity and expression, plasma clearance, and protein binding. 
 Mathematical models are being used increasingly to explore the impact of tumoral 
distribution47. They have several strengths including the ability to rapidly simulate a range in 
parameters, such as permeability or target expression, to understand the impact on distribution. 
Investigating these parameters solely with animal experiments would take a range of models at 
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increased time and cost. With mathematical simulations, parameters can be independently varied 
to isolate the impact of each, and values can easily be adjusted for the clinical scenario, which is 
ultimately the goal of the process. These mathematical models can also be used in designing 
focused animal experiments and interpreting the data, reducing the total number, time, and cost 
of these experiments while increasing confidence in the results.  
 The model used in this paper consists of a tissue and cellular level analysis of time 
dependent concentrations around blood vessels in tumors due to specific and non-specific 
mechanisms of uptake. Mathematically, it is a set of non-linear partial differential equations 
modeling the time-dependent concentration in two spatial dimensions. A graphical user interface 
(GUI) was developed to quickly modify the parameters used as inputs into the model (Fig. 2.8). 
By incorporating blood flow, extravasation, diffusion, and local binding and metabolism, a wide 
range of agents can be simulated and compared. This is in contrast to many models that make 
simplifying assumptions that limit the type of molecule that can be examined. For example, 
oxygen can quickly equilibrate across the blood vessel wall, but for agents such as antibodies, 
this would yield incorrect results. Compartmental models assume rapid diffusion through the 
tissue (no spatial gradients), which does not accurately capture many small molecules (e.g. 
doxorubicin and Hoechst 33342) and macromolecules (e.g. antibodies and nanoparticles). 
Models that assume uniform concentrations along the length of blood vessels (no axial gradients) 
may be valid for some drugs (e.g. highly plasma protein bound small molecules and biologics 
such as antibodies) while over-predicting uptake of small molecules with less plasma protein 
binding. By incorporating all the major steps in delivery to the tissue, the simulations are much 
more broadly applicable, and no simplifying assumptions need to be made a priori.  
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 Figure 2. 8 Graphical User Interface (GUI) for Krogh Cylinder Simulations 
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This PDE model predicts four broad classes of pharmacokinetic distribution in tumors. The first 
is blood flow limited agents. This class includes many small molecules that have low plasma 
protein binding, so they have a large free fraction that rapidly extravasates across the vessel wall. 
They quickly diffuse through the tissue (no diffusion limitations) and saturate the binding sites 
(no binding limitations). Examples of this type of agent are many small molecules in healthy 
tissue48. Here, the non-specific uptake is based on lipophilic distribution in the tissue. This is 
linear with drug logP values and tissue lipid content, and therefore it never saturates (unlike class 
IV). The short diffusion distances result in few to no interstitial transport limitations (unlike class 
III), and the small size allows rapid extravasation (unlike class II). The result is that the agents 
are blood flow limited, and compartmental models use this assumption in their development. 
 Large molecules like biologics have limited extravasation between the endothelial cells, 
resulting in permeability limited uptake. This can be seen in validated models for biologics51,52,56. 
Here, compartmental models assumed extravasation as the rate-limiting step, and these models 
focus on exchange between the tissue and vascular system based on convective and diffusive 
mechanisms. For tumors, elevated interstitial pressure results in diffusive uptake being the 
dominant mechanism65,66, but healthy tissue has significant convective extravasation and 
lymphatic drainage67. The heterogeneity often seen with antibodies can be captured with this 
model. The heterogeneity results due to rapid binding relative to interstitial transport (diffusion) 
and not directly because of low permeability. Cetuximab rapidly binds to the millions of 
receptors on the A431 cells before it can diffuse away from the vessel. Only after the cells 
adjacent to the vessel are saturated do the antibodies diffuse deeper into the tissue. 
Internalization and metabolism by these cells may permanently prevent this from occurring68. 
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Lower affinity antibodies can dissociate and diffuse farther in the tissue resulting in more 
homogeneous distribution69,70, although the rate-limiting step in uptake is still extravasation. 
 Diffusion limited drugs are often the least reported in the literature. These agents cannot 
be easily simulated with compartmental models due to the spatial gradients that develop in the 
tissue71. A typical class III agent is a small molecule (that can extravasate quickly, unlike class 
II) with high plasma protein binding (which buffers the free drug concentration along the length 
of a capillary, preventing class I designation). It may also have a non-saturable mechanism of 
localization (e.g. high uptake in membranes) or high target expression (DNA binding of Hoechst 
dyes), so it is not limited by binding or metabolism. Unlike other classes that may be either 
homogeneous or heterogeneous in tissue, this molecule must have spatial gradients within the 
tissue. 
 The final class of agent, class IV or binding and metabolism-limited agents, cannot be 
generalized based on their physiochemical properties and can encompass small molecules and 
macromolecules with widely varying properties. These agents saturate their binding sites with 
additional probe that lacks free target to engage (or enzyme for activation64). With no more 
targets (binding site limited), the extra probe intravasates back into the blood. Because of this, 
the uptake in a particular tissue is correlated with the number of targets, which is ideal for 
imaging agents. For Integrisense, a low number of targets gave a low overall signal, and 
increasing the number of αvβ3 binding sites in the tissue resulted in a much higher uptake in the 
tissue61. This intuitive result is often not the case for other agents such as antibodies40. Therefore, 
class IV agents are ideal for quantitative imaging. 
 Multichannel imaging allows the direct observation of distribution of multiple agents 
within the same tissue (Fig. 2.4). By stitching together images taken at high resolution, the 
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pattern of uptake across the entire tumor could be reconstructed. Comparing different drugs in 
the same tissue, the differences can be directly attributed to drug properties and not variability in 
the tumor microenvironment, strengthening the conclusions. BODIPY-FL was chosen as a class I 
agent due to its small size, relatively low plasma protein binding (for a fluorophore), and green 
fluorescence which did not interfere with the other three agents. The higher blood flow velocity 
in liver tissue (70-500 µm/s72,73) relative to tumors (20-200 µm /s74) resulted in higher uptake in 
the liver than in the tumor. Cetuximab-AF750 extravasated from functional vessels and gave a 
perivascular pattern of uptake typical of high affinity biologics against highly expressed 
targets37,75,76. Hoechst 33342 has a high level of plasma protein binding (99.3%), so it fills the 
functional vessels within the tumor without significant depletion and has long been used as a 
measure of perfused vessels58,59. This can be seen by comparing CD31 staining with Hoechst 
33342 and cetuximab-AF750, where several CD31 stained vessels show a complete lack of 
Hoechst or cetuximab staining indicating the vessel had collapsed prior to injection of any of the 
agents. Integrisense-680 had staining throughout the tumor and lacked the perivascular pattern of 
cetuximab-AF750 and Hoechst 33342. The large dose injected relative to the low target 
expression resulted in a saturation of the binding sites and a more even distribution. 
 Using the high-magnification images, the pattern around individual vessels could be 
examined (Fig. 2.5). Within the tumor, little BODIPY-FL could be distinguished, although the 
average signal was statistically higher than negative control tumors (p < 0.01). Any probe 
entering the tumor quickly diffuses away from the vessel. Although we used a cross-linking 
agent to covalently fix the molecule to the tissue, some of the drug may have washed away 
before it reacted. The higher levels in the liver still resulted in significant signal for this blood 
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flow limited agent. The Integrisense-680 signal is higher (due to binding) and stains cells 
throughout the tumor, both consistent with model predictions.  
Comparing the cetuximab-AF750, Hoechst 33342, and CD31 staining, there are some 
CD31 vessels that stain for only cetuximab or Hoechst 33342. Unlike CD31 vessels that lack 
both probes and are likely collapsed, staining of only one compound shows that it was 
functioning at some point during the experiment. Transient blood flow in tumor vessels is a well-
known phenomenon where the disrupted pressure gradients result in transient cessation and even 
reversal of flow77. Cetuximab-AF750 was injected 24 hrs prior to sacrifice, while Hoechst 33342 
was injected 3 hrs beforehand. It is therefore not unexpected that some vessels would stain with 
the cetuximab-AF750 and then stop functioning at some point before the injection of Hoechst 
33342. However, since the antibody is present the entire time Hoechst 33342 is in the blood, 
vessels that stain only with Hoechst 33342 are not expected. The likelihood of a vessel not 
functioning for the 21 hrs between the injections and then suddenly functioning for a few 
minutes after the Hoechst 33342 injection (where the majority of uptake occurs before its rapid 
clearance) is also low. This has been seen in other tumor models as well with Trastuzumab 
antibody and DIOC7 as a vascular stain75. One explanation is that the injection itself, either the 
probe or agents in the formulation, can alter blood pressure and tumor blood flow78, resulting in 
induced changes in blood flow patterns. If the contrast is increased on the cetuximab-AF750, 
there is staining around the vessels that initially appear to be stained only with Hoechst 33342 
indicating that there was antibody in these vessels when they were delivering Hoechst 33342. 
Therefore, we hypothesize that the injection of Hoechst altered the tumor blood flow, resulting in 
these patterns and consistent with transient blood flow and model predictions.      
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 Despite the established use of Hoechst 33342 to stain functional vessels in tumors, the 
kinetic rates of uptake have not been measured in much detail79,80. It has been reported that the 
uptake of a very similar dye, Hoechst 33258, is much slower. Different modes of binding and 
diffusion have been postulated for biologics and we wanted to see if small molecules could 
follow the same patterns. The modes include fast or slow binding and fast or slow dissociation. 
High-affinity antibodies exhibit fast association and slow release, and it appears Hoechst 33342 
follows this pattern of quickly entering the cell, binding the target, and dissociating slowly. 
However, if Hoechst 33258 entered cells at a rate much slower than diffusion through the tissue, 
then it could distribute more homogeneously before entering the cells (effectively immobilized) 
and binding to the DNA. In vitro cell culture experiments showed saturation after 15 min with 
Hoechst 33342 versus 2 hours with Hoechst 33258, and the modeling data indicated that the 
Hoechst 33258 would distribute more homogeneously (albeit at a lower concentration per cell, 
Fig. 4). After injecting the same dose, this was exactly what was observed in vivo. We could not 
quantitatively compare the images since the intensity differences were too great to image both at 
the same microscopy settings (Hoechst 33342 was saturated at the settings required for Hoechst 
33258). However, qualitatively, the pattern and intensity were consistent with predictions (Fig 
2.6). This example, where simply switching an ethoxy group to a hydroxyl group results in such 
a drastic change in distribution, is one reason why predictions based exclusively on structure 
(and no in vitro experiments) remain challenging. This also provides an example where modeling 
helps explain a counter-intuitive situation where rapid cell uptake results in poor distribution and 
poor cell uptake yields a more homogeneous distribution. 
 The modeling for the Hoechst dyes required a separate code to accurately simulate the 
distribution. The code used previously for antibodies81 and small molecules47,53 was based on a 
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simplifying assumption for diffusion. Antibodies do not cross cell membranes, so diffusion 
occurs exclusively in the extracellular space, and the other small molecules crossed cell 
membranes fast enough to equilibrate between the intracellular and extracellular space relative to 
diffusion. The Hoechst dyes straddled these two extremes where the cellular uptake rate was on 
the same time-scale as diffusion in the tissue. Therefore, the cellular uptake rate had to be 
explicitly modeled in the equations. 
 For Integrisense-680, modeling predictions indicated the dose was much higher than 
necessary for saturation, and a low level of uptake was expected throughout the tumor. In regions 
primarily consisting of A-431 cells, there is a Pearson correlation coefficient of 0.55. However, 
in non-tumor cells, the Integrisense-680 signal is slightly higher. This could be due to αvβ3 
binding sites on macrophages82,	 although the antibody reportedly cross-reacts with mouse 
antigen. Alternatively, we calculated whether fluid phase uptake would be sufficient for the 
higher macrophage signal. Although particle shape35, surface	coatings83,84,	and	size85,86	affect 
uptake, even PEGylated molecules that have low interaction are taken up by these cells38. Using 
a previous estimate of fluid phase uptake by activated macrophages in the model64, the predicted 
concentration from non-specific fluid phase uptake was twice that of the binding to A431 cells. 
Either binding or fluid phase uptake could contribute to the higher macrophage uptake than A431 
cell uptake, but they are both consistent with a lack of transport limitations and uptake limited by 
local binding or (fluid-phase uptake and) metabolism. 
 Cetuximab-AF750 is limited by extravasation based on previous reports34,53. The dose 
used was sub-saturating, so only cells adjacent to blood vessels were labeled. This results in a 
lower Pearson correlation coefficient. A larger dose would saturate all the binding sites and 
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result in a more homogeneous distribution (and higher Pearson correlation coefficient) as shown 
in tumor spheroids68 and xenografts37,87.  
 One of the biggest hurdles to using models in research is the extensive effort required to 
develop a model and parameterize all the rates. Although software exists for compartmental 
models, the assumptions for compartmental models are sometimes valid and other times not88. 
To facilitate the use of this partial differential equation model, we have generated a graphical 
user interface (GUI) for the simulations. This allows a user to quickly simulate a wide range of 
agents, from small molecules to biologics and nanoparticles, without coding. The tumor 
physiology parameters can also be varied to study the impact on distribution in a matter of 
seconds, facilitating the use of the model in designing experiments and interpreting results. 
2.6 Conclusion 
In conclusion, we have used multi-channel imaging of four agents in a tumor and 
compared the distribution to a partial differential equation model. The model distinguishes four 
different rate-limiting steps in uptake, which has practical applications in combination therapies 
that normalize the vasculature21,89, which may have synergistic or antagonistic effects. 
Experimentally, this group of agents could be used in conjunction with radiolabelled probes. By 
combining the fluorescent agents with autoradiography of an imaging agent or tritiated 
therapeutic, a comparison can be made between the new probe and the known fluorescent agents. 
This can help parse out the distribution of the radiolabelled agent due to target interaction versus 
the local tumor microenvironment90,91. Together, a combined theoretical and experimental 
approach can help in designing experiments, interpreting animal results, and developing 
improved therapeutics and imaging agents.	
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2.7 Experimental Methods 
Mathematical model 
 The mathematical simulations were based on a previously published model53. Briefly, the 
model consists of non-linear partial differential equations with axial and radial gradients around 
a Krogh cylinder representation of tumor vessels. Time-dependent mixed boundary conditions 
determine the extravasation and depletion along the length of the vessel, and diffusion across a 
pseudo-homogeneous tissue with saturable binding and local metabolism dictate the tissue 
distribution. Equations are solved using finite differences in MATLAB (Mathworks), and a 
sparse Jacobian is specified to reduce computation time. Parameterization is also challenging 
with literature values often sparse and sometimes contradictory, especially for small molecules 
where equilibrium values are more readily available than kinetic rates. A table of parameters 
used in the predictions is listed in the supplementary data. 
 
Differential equations for Graphical User Interface simulations: 
 
1.  !!!"!#$!" = 𝐷!"" !! !!!"!#$!" + !!!!"!#$!!! + !!!!"!#$!!! − !!"#$! 𝐶!"!#$ 𝑇! − 𝐵 + 𝑘!"#"$%"𝐵 
 
2.  !!!"#$%&&!" = 𝑅! − !!"#$! 𝐶!"!#$ 𝑇! − 𝐵 + 𝑘!"#"$%"𝐵 − 𝑘! 𝑇! − 𝐵  
 
3.  !!!"#$%&&!" = !!"#$! 𝐶!"!#$ 𝑇! − 𝐵 − 𝑘!"#"$%"𝐵 − 𝑘!𝐵 
 
4.  
!!!"#$%#!" = −𝑣 !!!"#$%#!" − !!!!! !!"# 𝑓!"##𝐶!"#$%# − !!"!#$!  
 
Boundary conditions: 
 
1.  !!!"!#$!" !!!!"#$! = !!!"!#$!" !!! = !!!"!#$!" !!! = 0 
 
2. 𝐷!"! !!!"!#$!"  !!!"# = 𝑃 𝑓!"##𝐶!"#$%# − !!"!#$!  
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3. 𝐶!"#$%# !!! = 𝐶!"#$%#,! 𝐴𝑒!!! + 1− 𝐴 𝑒!!!  
 
4. 
!!!"#$%#!" !!! = 0 
 
Initial conditions: 
 
1. Ctotal = Boverall = Cplasma = 0 
 
2. Toverall = T0 
 
 
 
Mathematical equivalence of epsilon (void fraction) and R (immobile fraction) 
 
Cimmobile = RCfree 
 
Ctotal = Cimmobile + Cfree = Cfree(1 + R)  and  𝐶!"## = !!"!#$!!!  
 
Assuming only the free fraction can diffuse and bind. The concentrations are in terms of total 
drug, so total drug concentrations are divided by 1+R. 
 
For antibodies and other biologics that cannot enter cells, the total tissue concentration 
(moles per total tissue volume) is averaged over both intracellular and extracellular space. Since 
the molecules are confined to the extracellular space, the effective concentration is higher than 
the total average, so the total concentration is divided by epsilon. 
 𝐶!!!"#$%&" = 𝐶!"!#$𝜀  
 
While the terms both convert the total tissue averaged concentration to an effective 
concentration, they have opposite effects on the magnitude. The void fraction, epsilon, varies 
between 0 and 1, so dividing by this value increases the effective concentration. For small 
molecules that are often highly immobilized to proteins and membranes, the free concentration is 
often lower than the total concentration, and R is generally much larger than 1. This is analogous 
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to how the volume of distribution can be much larger than the tissue volume of a small molecule 
drug, since the free concentration can be a small fraction of the total concentration. 
Note that the effective diffusion coefficient must still be adjusted by the immobile fraction 
(relative to the diffusion coefficient when all the drug is free in solution): 
For the diffusion coefficient, it is assumed that whatever fraction is bound to proteins or 
taken up by membranes is the same inside and outside the cell. It is also assumed that this 
binding happens immediately in the extracellular compartment, so the effective diffusion 
coefficient is scaled by the factor R. This also occurs for the boundary condition, so the free drug 
able to intravasate is adjusted by R. 
 
From Crank92: 
 𝜕𝐶!"##𝜕𝑡 = 𝐷∇!𝐶!"## − 𝜕𝐶!""#$!%!𝜕𝑡  𝜕𝐶!"##𝜕𝑡 = 𝐷1+ 𝑅 ∇!𝐶!"## 
 
Multiply both sides by the constant (1+R): 𝜕𝐶!"## 1+ 𝑅𝜕𝑡 = 𝐷1+ 𝑅 ∇! 1+ 𝑅 𝐶!"##  𝜕𝐶!"!#$𝜕𝑡 = 𝐷1+ 𝑅 ∇!𝐶!"!#$ = 𝐷!""∇!𝐶!"!#$ 
 
 
 
 
Differential equations for Radial Only simulations 
 
1. Free Extracellular Drug 𝜕𝐶!"#,!"#$%&&𝜕𝑡 =  𝐷!"" 1𝑟 𝜕𝜕𝑟 𝑟 𝜕𝐶!"#,!"#$%&&𝜕𝑟 − 𝑘!" 1− 𝜀𝜀 𝐶!"#,!"#$% ! + 𝑘!"#𝐶!"#,!"#$%&& 
 
2. Intracellular Drug 𝜕𝐶!"#,!"#$%&&𝜕𝑡 = 𝑘!" 1− 𝜀𝜀 𝐶!"#,!"#$%&& − 𝑘!!"𝐶!"#,!"#$%&&− 𝑘!"1− 𝜀 𝑅 (𝑇!,!"#$%&& − 𝐵!"#$%&&)𝐶!" ,!"#$%&& + 𝑘!""𝐵!"#$%&& 
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3. Bound Drug 𝜕𝐵!"#$%&&𝜕𝑡 = 𝑘!"1− 𝜀 𝑅 (𝑇!,!"#$%&& − 𝐵!"#$%&&)𝐶!"#,!"#$%&& − 𝑘!""𝐵!"#$%&! 
 
Boundary Conditions 
 
1.  !!!"#,! !"#$$!" !!!!"#$! = 0 
 
2. 𝐷!"" !!!"#,!"#$%&&!" !!!!"# = 𝑃 𝑓!"##𝐶!"#$%# − !!"#,!"#$%&&! !!!  
 
Initial Conditions 
 
1. Cext,overall = Cint,overall = Boverall = 0 
 
 
 
Summary of Parameters for Simulations 
 
Bodipy FL 
In vitro live cell imaging showed the intracellular signal of BODIPY-FL was twice that of the 
extracellular signal, so epsilon was set to 2. The hydrodynamic radius for BODIPY-FL is ~85% 
that of olaparib-BODIPY FL. Scaling the permeability from Thurber et al. 2014 between 
olaparib-BODIPY FL and oxygen, this results in a 20 um/s permeability. For simulations in the 
liver, the velocity was set to 70 µm/s73. The value did not change for higher flow rates of 0.5 
mm/s 72. An equivalent residence time occurs for a velocity of 25 µm/s and vessel length of 180 
µm, which was used in the GUI. 
 
Hoechst 33342 – Full Krogh cylinder simulation 
For the cellular uptake model (radial distribution only), the on rate is calculated assuming all of 
the drug can bind to the target. (For example, assuming instant equilibration between the total 
extracellular concentration and intracellular concentration, the intracellular concentration is 
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increased by a factor of R over the total extracellular concentration (bound plus free). This is 
divided by R to result in a rate based on the total extracellular concentration. For the full Krogh 
cylinder model, only the free drug can bind, so for consistency with the radial distribution model, 
the Krogh cylinder model on rate has to be multiplied by the bound to free ratio, R, which is 
equivalent to epsilon.  
The permeability was scaled using a hydrodynamic radius of 0.7 nm from Schmidt et al. 2009 
and permeability from Thurber et al. 2014 
 
Integrisense-680 
Permeability is based on 1.432 kDa molecular weight, Schmidt et al. conversion to 
hydrodynamic radius and permeability.  
The tumor is saturated after 30 min, but imaged after 24 hrs when most of the probe has been 
internalized. To show the saturation, the simulations are run for 30 min. 
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Table 2.2 Parameters for Krogh Cylinder Simulations 
 
Bodipy FL 
in Tumor 
Cetuximab-
AF750 
Hoechst 
33342 
 
Integrisense 
680 
Hoechst 
33342 (radial 
only) 
Hoechst 
33258 (radial 
only) 
Dose 50 nmol 30 ug 300 ug 
(15 mg/kg) 
2 nmol 300 ug 
(15 mg/kg) 
300 ug 
(15 mg/kg) 
C0 4.54 µM* 143 nM* 348 µM** 1.4 µM 348 µM** 343 µM** 
Diffusion 
Coefficient 
40 um2/s 10 um2/s 100/80 um2/s 40 um2/s 200/80 um2/s 200/20 um2/s 
Permeability 20 um/s 0.003 um/s 10 um/s 0.3 um/s 4.7 um/s 0.46 um/s 
kon NA 105/M/s ε*15000 
/M/min 
or 
2x104/M/s 
105/M/s 15000 /M/min 500 /M/min 
kin NA NA assume instant 
equilibration 
NA 1.5/min 0.25/min 
Kd NA 0.3 nM 1.42 nM93 4.1 nM 1.42 nM93 1.42 nM93 
Epsilon (ε) 2* 0.2 80 0.4 80** 20** 
S/V 60/cm* 60/cm* 60/cm* 60/cm 60/cm* 60/cm* 
Plasma 
volume 
1.4 mL 1.4 mL 1.4 mL 1.4 mL 1.4 mL 1.4 mL 
Capillary 
radius 
8 µm 8 µm 8 µm 8 µm 5 µm 5 µm 
Vessel 
Length 
500 µm 500 µm 500 µm 500 µm NA NA 
Fraction 
Bound 
89.7%  
+/-3.8%* 
0 
 
99.3%  
+/-0.4%* 
94.9%  
+/-2.3 * 
 
99.3%  
+/-0.4% 
98.8%  
+/-0.9%* (high 
affinity to 
albumin94) 
Hematocrit 0.45 0.45 0.45 0.45 0.45 0.45 
Receptors/ 
cell 
0 4 x106 85x106 (ref 95) 104 (ref 96) 85x106 (ref 95) 85x106 (ref 95) 
ke NA 1.9e-4/s 
or 
4.4e-6/s*** 
0 1.3e-5/s 
or 
4.4e-6/s97 
kin /R kin /R 
Fraction 
alpha 
0.562* 0.56* 0.99598 0.9297 0.99598 0.987* 
Alpha half 
life 
2.6 min* 3 hr* 2 min98 6 min 2 min98 1.3 min* 
Beta half life 30.4 min* 70 hr* 1 hr98 210 min 1 hr98 3.0 hr* 
Simulation 
time 
2 min 24 hrs 3 hrs 30 min 3 hrs 3 hrs *Measured	**Calculated	***	Cy5	Dye	is	trapped	within	cells	for	~44	hr	half	life		
For Bodipy FL in liver, the only differences were that the S/V was 580/cm and vessel length was 
180 µm.  
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Cell lines and Imaging Agents 
A-431 cells were obtained from ATCC (Manassas, VA). Cetuximab (Bristol-Myers 
Squibb; Princeton, NJ) was conjugated with Alexa Fluor 750 (Life Technologies; Eugene, OR) 
according to the manufacturer’s instructions. Anti-mouse CD31 (Biolegends; San Diego, CA; 
Cat. No. 102402) and anti-EGFR (R&D Systems; Minneapolis, MN; Cat. No. AF231) antibodies 
were labeled with Alexa Fluor 555 (Life Technologies; Eugene, OR) in a similar manner. 
Integrisense-680 (Perkin Elmer, Waltham, MA), Hoechst 33342, Hoechst 33258, and BODIPY-
FL propionic acid (Invitrogen, Grand Island, NY) were used without further purification.  
 Plasma protein binding of Integrisense-680, Hoechst 33342 and 33258, and BODIPY-FL 
propionic acid were measured using a Rapid Equilibrium Dialysis (Thermo Scientific; Rockford, 
IL) plate according to the manufacturer’s instructions. Mouse plasma (Innovative Research) was 
mixed with either 20 µM BODIPY FL, 50 µM of Hoechst dye, or 1 µM for Integrisense 680. 
After equilibration, the buffer in each chamber was adjusted to 50/50 mouse plasma and PBS to 
eliminate effects of protein binding on fluorescence. The signal was measured using either a 
SpectraMax M5 Microplate (Molecular Devices; Sunnyvale, CA) reader or Odyssey CLx (Licor; 
Lincoln, NE). 
 
In vitro experiments 
A-431 cells were plated overnight in 96-well plates. Hoechst dyes were diluted with L-15 
media (without phenol red) and 10% FBS to concentrations of 10 and 100 µg/ml each. A 
Microplate reader maintained at 37°C was used to measure fluorescence (excitation 350 nm, 
emission 450 nm), and the signal was background subtracted using wells with no cells. 
Experiments were conducted in triplicate, averaging 5 wells each time.  
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 The kinetic rates of cellular uptake were determined by using a two-compartment model 
to fit the experimental data shown below. The probe was assumed to cross the plasma membrane 
by passive diffusion79,80 into an intracellular compartment and then transport to the nucleus and 
bind the DNA. When combining with the PDE model, the intracellular probe was considered 
immobile. 
Assumptions:  
1) Extracellular concentration is constant 
2) Equilibrium is maintained between intracellular free drug and intracellular membrane bound 
drug 
3) Amount of target (DNA) is constant (To=T+B) 
The final equations used to model the system are: 
!!!!!  =  𝑘!" 𝐶! −  𝑘!"# 𝐶! − !!" !!"#!!" 𝐶!  𝑇! +  (𝑘!"" + !!" !!"#!!" 𝐶!  ) B         !"!" =  !!" !!"#!!" 𝐶!  𝑇! − (𝑘!"" + !!" !!"#!!" 𝐶!) B            
where, Ci and Ce (M) are the drug concentrations in the intracellular and extracellular 
compartment; kin and kout (min-1) are the rates of cellular uptake and loss of the drug from the 
cell; kon and koff (M-1 min-1) are the binding and dissociations rate constants, respectively; and T0, 
T, and B (M) are total, unbound, and bound target sites (DNA), respectively. The solution to 
these equations was fit to the experimental data to determine the rate constants using fmincon 
constrained optimization algorithm in MATLAB (Mathworks; Natick, MA).  
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Figure 2.9 Cellular uptake model and experimental data for both Hoechst molecules 
(Top) Two compartment model used to derive the coupled ODE’s for Hoechst uptake. (Bottom) 
In vitro cellular uptake data for both molecules. MFU = Background subtracted mean 
fluorescence units.  
 
In-vivo Experiments 
A-431 cells were used to grow tumor xenografts in nude mice (Jackson Laboratory; Bar 
Harbor, ME). All experiments involving mice were conducted in compliance with the University 
of Michigan University Committee on Use and Care of Animals (UCUCA). The cells were 
harvested using Trypsin-EDTA (0.05%), resuspended in PBS at a concentration of 1.5 million 
cells/50 µL, and injected subcutaneously in each hind limb while the mouse was anesthetized 
using isoflurane at 2% and 1 L/min oxygen.  When the longest axis of the tumor was 5–10mm, 
0.2 nmoles of Cetuximab and 2 nmoles of Integrisense 680 were injected intravenously 24 hours 
before euthanizing the mouse. 15 mg/kg of Hoechst 33342 or 33258 and 50 nmoles of Bodipy 
FL were injected 3 hours and 2 minutes before euthanizing, respectively. The tumors were then 
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resected along with the liver, snap frozen in OCT compound using isopentane cooled with dry 
ice. The tumors and liver were sectioned into 6 µm slices on a cryostat.  
Slides were imaged using an upright Olympus FV1200 confocal microscope equipped 
with 405, 488, 543, 633 and 750 nm laser lines. High-resolution images of the entire tumor were 
created by stitching together individual images taken with a 20X objective and a motorized 
stage. Since BODIPY-FL was the only drug not bound to a target, these slides were pretreated 
with Ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC) (Sigma Aldrich; St. Louis, MO) 
before imaging this channel. 75 µl of a 0.5M solution of EDC in PBS was added to the tissue for 
15 min followed by a 3x3 minute wash with PBS.  
For ex-vivo labeling of EGFR, slides were incubated with 75 µl of a 20 nM solution of 
Alexa Fluor 555 conjugated anti-EGFR antibody at room temperature for 25 minutes followed 
by a 3x3 minute wash with PBS. The anti-mouse CD31 antibody was imaged in a similar 
manner. For integrin staining, slides were incubated at room temperature for 25 minutes with 75 
µl of a 20 nM solution of a primary anti-αvβ3 antibody (R&D Systems; Minneapolis, MN; Cat. 
No. MAB 3050), followed by a 3x3 minute wash in PBS, 15 minute incubation in 75 µl of a 40 
nM solution of the secondary anti-rabbit-TRITC (Sigma Aldrich; St. Louis, MO; Cat. No. 
T6778), 3x3 minute wash, and imaged. JACoP, a plug-in in FIJI, was used to analyze the in-vivo 
and ex-vivo labeling and generate a Pearson correlation coefficient99.  
 
Plasma Clearance 
Plasma clearance studies of the drugs were conducted on C57BL/6J mice. The agents 
were dissolved in 75 µl of PBS and injected intravenously via the tail vein. Samples were 
obtained retro-orbitally or from the saphenous vein using heparin coated capillary tubes. 10 µl of 
41		
the blood was mixed with 20 µl of PBS-EDTA and centrifuged to remove cells. Plasma was 
pipeted into a 384 well plate, and the signal was measured on a Microplate reader or Odyssey.  
 
	 	
Figure 2.10 Plasma clearance curves for Hoechst 33258, Cetuximab and Bodipy FL. 
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Chapter 3: Orally Available Near Infrared Imaging Agents 
3.1 Publication Information 
Bhatnagar S, Verma KD, Hu Y, Khera E, Priluck A, Smith DE, Thurber GM 2018. Oral 
Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic 
Mouse Model for Breast Cancer Screening. Molecular pharmaceutics  15(5):1746-1754.  
Modifications have been made to the published document to adapt the content to this 
dissertation. 
3.2 Abstract 
The early detection of diseases can have a profound impact on patient outcomes. Annual 
screenings in high-risk populations can assist in the early detection of these diseases but the 
implementation of annual screenings can be an issue with low compliance rates. The 
development of a technique, as proposed in this dissertation, of orally available near infrared 
imaging agents can help improve compliance rates, as the technique is completely non-invasive 
and safe with the use of non-ionizing radiation. The reason this technique is novel and has not 
been developed earlier is that orally available agents and imaging agents have very different 
properties. Orally available agents generally have low molecular weights and are lipophilic 
whereas imaging agents have higher molecular weights and are hydrophilic. This chapter deals 
with the synthesis of five different imaging agents to determine the combination of properties 
that would allow for an efficient orally available imaging agent. Out of the five imaging agents 
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studied, the IRDye800CW agent had good physicochemical properties and sufficient oral 
absorption to have promise in the detection of diseases in mouse models.  
3.3 Background 
The ability to non-invasively detect sites of disease for early diagnosis and treatment 
remains a desirable but elusive goal in medicine. In cancer, for example, detection of stage 1 
cancers is associated with a greater than 90% 5-year survival rate, and identification of 
premalignant lesions often results in a cure1, providing a strong incentive for early detection. 
Two of the standard methods of detection involve minimally invasive blood tests and medical 
imaging100, each with benefits and drawbacks. Blood tests generate large amounts of molecular 
information but lack spatial information to identify the source of the biomarker. Imaging 
modalities can pinpoint precise locations but typically only yield anatomical data. Molecular 
imaging modalities can provide both, but these involve radiation and/or high cost, prohibiting 
their use in widespread screening of healthy populations with low incidence rates101. Orally 
available near infrared imaging agent have significant advantages over both blood testing and 
current clinical imaging modalities. This technique can be used for completely non-invasive, 
non-ionizing molecular imaging for disease diagnosis.  
A primary advantage of blood tests is the comprehensive sampling of body tissues due to 
the efficient exchange of molecules within the circulatory system. However, this also serves as a 
major drawback. The lack of spatial information requires identifying molecules specific to the 
site of disease, and the large dilution of biomarkers in the systemic circulation and interstitial 
fluid requires exquisite sensitivity that until recently precluded bedside diagnosis102,103. 
Variability in secretion, metabolism, and excretion rates further erodes the sensitivity and 
specificity of blood tests, particularly for the early diagnosis of cancer104. Despite the tremendous 
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incentive to develop methods for early detection, these drawbacks have so far eluded attempts at 
generating a universal blood screening test for cancer105,106.  
Medical imaging covers a suite of modalities including X-rays, X-ray computed 
tomography (CT), magnetic resonance imaging (MRI), ultrasound (US), nuclear imaging 
(positron emission tomography - PET and single-photon emission computed tomography - 
SPECT), and non-ionizing radiation (near-infrared fluorescence and spectroscopy). Compared to 
blood tests, these methodologies yield precise spatial information from centimeter down to 
subcellular resolution107. However, these modalities lack the molecular information provided by 
blood tests, hampering their sensitivity and specificity.  
Molecular imaging provides the promise of combining spatial and molecular 
information10. However, the prevalent use of ionizing radiation in these techniques (PET and 
SPECT) makes the cost-benefit ratio inappropriate for widespread screening of diseases with low 
incidence rates without pre-selection108,109. While progress is being made, safer alternatives that 
lack ionizing radiation such as microbubbles in ultrasound110,111 and nanoparticle MRI contrast112 
have yet to provide large-scale clinical applications in screening. Topical applications reduce 
systemic exposure to the probe but are restricted to certain tissues and surgical applications113-115. 
The high costs of several screening modalities, such as PET, SPECT, and MRI, can also be 
prohibitive in large populations when incidence rates are low109,116. 
Near-infrared light has been used for several decades as both a research tool and in 
clinical applications. Introduced in the 1950’s117, indocyanine green is employed as a 
fluorescence marker in the clinic, primarily as a vascular agent due to its high plasma protein 
binding and hepatic clearance indicator due to exclusive removal by the liver into the bile118-121. 
Recently, NIR imaging has garnered increased attention as fluorescent dyes and imaging 
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equipment have become more prevalent and commercially available122. The photophysical 
properties of fluorescence can also be leveraged to provide mechanistic and microenvironmental 
details38,123-127. While visible light can generally only penetrate several cell layers into tissue 
before scattering and absorption degrade the signal intensity, NIR light in the 650 – 900 nm 
‘window’ can penetrate centimeters into tissue with much lower scattering and absorption17,19. 
Scattering and absorption (primarily from hemoglobin) of NIR light has long been used for non-
invasive measurement of blood oxygenation and is currently being investigated for detection of 
oral and breast cancers128,129 and functional mapping of the brain surface130 in the clinic. 
Importantly, the autofluorescence signal from tissue in the NIR window is extremely low, 
providing high sensitivity and target-to-background ratios (TBR) even with low signal from 
deeper inside tissue16,17,19,131. Recently, time resolved fluorescence imaging has been used to 
image cerebral blood flow underneath the skull for stroke detection132,133 and through the hand 
for early diagnosis of rheumatoid arthritis134,135.  
NIR techniques have similar challenges for screening that are faced by other imaging 
modalities. Applications that do not use exogenous probes are primarily detecting anatomical 
(histological) changes that may be confounded by inflammation, fibrosis, or other benign 
conditions for cancer screening. Imaging probe-based techniques can target specific disease-
associated molecules, but the invasive delivery mechanism (e.g. intravenous infusion of ICG) are 
better suited to populations with a high probability of benefit136 (such as a cancer or stroke 
patient). NIRF has been successfully used in angiograms of the eye137, imaging the cerebrospinal 
fluid138, hepatic function19, and colon polyp identification19,115, among several others. One rapid 
area in growth is the development of intraoperative imaging agents for more complete resection 
of tumors and visualization of vascular and nerve tissues for surgical guidance139-143. However, 
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intravenous delivery is not conducive to widespread screening of large populations with low 
incidence. The other feasible routes of administration are oral and sub-cutaneous, which would 
allow patients to self-administer the imaging agent.   
The advantages of oral over intravenous or subcutaneous administration can be grouped 
into three categories: safety, cost, and compliance (Table 3.1). Although the risk of serious 
reactions to imaging agents is low (e.g. 0.05-0.2% for moderate to severe reactions from ICG144 
and 0.01-0.2% for severe reactions to iodine contrast agents145), these can still be unacceptably 
high when testing a large and potentially healthy population. For reference, there are ~40 million 
mammograms in the US each year146. Oral delivery is generally the safest route and can 
sometimes drive tolerance rather than sensitivity. The cost of intravenous and subcutaneous 
administration is generally higher given the requirement for sterile delivery. This is particularly 
acute for intravenous delivery, where the additional medical costs of personnel administration 
and monitoring can far outweigh any change in the cost of materials that are ~$1 per day for 
small molecule drugs or cents per day with generics147. In addition, patients strongly prefer SC 
delivery to IV (91.5%148) and oral delivery to SC (93%149). Medical personnel also prefer SC 
delivery due to fewer complications than IV148. Finally, the finite clearance rate of imaging 
agents often requires a waiting period of several hours after administration such as folate-
targeted agents139 and ICG150,151. Given the low compliance rates for mammography without 
required multiple visits (e.g. first visit for intravenous administration and safety monitoring 
followed by a second visit for imaging) or an extended visit (remaining at the imaging location 
for several hours), this could severely compromise compliance. 
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Table 3.1 Criteria of selecting route of administration 
 
 Intravenous (IV) Subcutaneous (SC) Oral (PO) 
Safety Allergic reactions seen more often after parenteral 
than oral delivery (e.g. penicillin, iron 
supplements152,153)** 
Generally considered 
safest route; often used 
for de-sensitization154 
Cost Highest – sterile 
material, medical 
supervision, low 
material cost 
Moderate – sterile material, 
possible training, low 
material cost 
Low – no training or 
monitoring by medical 
personnel, moderate 
material cost 
Compliance*  
patient 
preference 
91.5% of patients 
prefer SC 
administration to 
IV148 
93% of patients prefer PO 
delivery to SC149 
Preferred route of 
administration by 
patients. 
Compliance*  
logistics 
Extended visit 
(multiple hours) or 
two separate visits 
required 
Self-administration 
feasible, but may require 
training 
Simple self-
administration, no 
training required 
* - US compliance rates (without any imaging agent administration) range between 70-80%155 
** - Anaphylaxis is a life-threatening condition that can present within minutes to hours after 
exposure156. May require monitoring particularly after intravenous administration. 
 
 Most of the above mentioned benefits are exclusive to administration for screening 
purposes in a healthy population. For patients undergoing potentially life-saving surgery like 
cancer resection, the required hospitalization and monitoring mitigates the cost-benefit ratio for 
oral delivery. Likewise, the cost of intravenous delivery relative to surgery is negligible. 
Compliance rates may still favor oral delivery if the patient needs to make multiple visits to the 
hospital, but administration immediately before surgery or during a preoperative visit would 
lower this benefit. 
One major reason why oral administration of molecular imaging agents has never been 
reported previously is the disparate physicochemical properties required for oral absorption 
versus efficient targeting. It is widely appreciated that high oral bioavailability for drug-like 
compounds requires low molecular weight (< 500 Da) and high lipophilicity157. In contrast, 
efficient targeting agents often favor higher molecular weights for specific binding and low 
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lipophilicity to reduce off-target interactions. Hydrophilic molecules are generally poorly 
absorbed, and negatively charged drugs have even worse absorption. For example, the FDA 
approved drug, alendronate, has only 0.7% oral bioavailability in humans (0.2% in mice) despite 
its small size (250 Da)158. Aside from bioavailability, the binding affinity and retention of these 
molecular imaging agents must be high enough to target the receptor and be retained over the 
long period of time between the absorption/clearance phase and imaging. Overall, orally 
delivered molecular imaging probes require stability in the gut, intestinal absorption, low first-
pass extraction in the liver, efficient targeting from the systemic circulation, background 
clearance, and compatible optical properties for detection at clinical depths 
 In order to overcome the significant challenges of orally delivering imaging agents, we 
developed a series of imaging agents with the same targeting ligand and varying NIR 
fluorophores to create imaging agents with a wide range of physicochemical properties. Testing 
these in vitro and in vivo helped determine what properties were most important for orally 
available imaging agents.  	
3.4 Results 
The criteria in table 3.2 were selected for our proof-of-concept studies. While not all 
these criteria are necessary for developing orally administered molecular imaging agents, they 
were used to provide the highest chance of success in the shortest development time. We selected 
a low molecular weight targeting ligand against integrin receptors. This extracellular target has 
high expression on several cell types (e.g. in cancer - activated endothelium, macrophages, and 
tumor cells) for robust expression. Importantly, the target also internalizes with a sufficient rate 
for trapping the imaging agent over extended periods of time. This target also has a series of 
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targeting ligands developed against it for therapeutic purposes60,159-162. Many of these agents 
have gone through rounds of medicinal chemistry optimization for high oral bioavailability such 
as chemical stability in the GI tract, low first-pass metabolism, moderate plasma protein binding,  
and low toxicity. This agent has also been shown to maintain targeting following conjugation to 
several fluorophores97, allowing us to manipulate the physicochemical properties while 
maintaining target binding163.  
Transport analysis indicates these molecules are likely binding-site and internalization 
limited164 meaning that reducing protein binding/colloidal interactions is not as important as 
permeability surface area product (PS/V) limited agents. Plasma protein binding also impacts 
systemic clearance rates, which determines the absolute uptake in target and non-target tissues. 
Because the background signal from these agents is close to autofluorescence, a reduction in 
total signal may lower the target signal while the background does not decrease significantly 
(because it is dominated by tissue autofluorescence), thereby lowering the target to background 
ratio. Therefore, plasma protein binding in this scenario increases the contrast.  
 
Table 3.2 Target and ligand selection design criteria 
 Criteria Rationale 
 
 
 
Target Selection 
(Integrin) 
 
Extracellular target Easily accessible from blood and rapid 
washout of unbound probe 
High expression in several cell 
types (tumor cells, macrophages 
and activated endothelium) 
Robust detection for screening and 
sensitivity with NIR imaging107 
Internalizes probe at a significant 
rate 
Lowers the required affinity165 
Well studied ligands against 
target 
Circumvent the molecular screening 
step 
 
 
Ligand Selection 
(Peptidomimetic) 
Low molecular weight Increase the oral absorption 
High stability Prevent protease and/or acid 
degradation in GI tract to increase oral 
absorption 
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Low toxicity Maintain large safety margin for 
screening potentially healthy patients 
Low first pass metabolism Low liver uptake/metabolism to 
increase oral absorption 
High affinity, maintained after 
conjugation with fluorophores 
Enable efficient and specific targeting 
even with variable plasma 
concentrations 	
Imaging Agent Synthesis 
 The structure of the peptidomimetic (2) and reaction scheme to generate the imaging 
agents (3) are shown in Fig. 3.1. The fluorophores selected used in this study were IRDye 
800CW, Alexa Fluor 680 (AF680), Sulfo-cyanine7 (Sulfo-cy7), CellTrace Far Red DDAO 
(DDAO) and Bodipy 650/665-X (Bodipy650).   
	
	
Figure 3.1 Reaction scheme for imaging agent synthesis 	
Imaging Agent Structures 
Figure 3.2 shows the structures of all five imaging agents with a constant targeting ligand 
that binds primarily to integrin αVβ3 and varying NIR fluorophores to change the physico-
chemical properties of the resulting imaging agents.  
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Figure 3.2 Structures of the imaging agents 	
Imaging Agent Properties 
All five imaging agents were tested for properties like affinity, plasma protein binding 
and logD in in vitro assays. These properties along with the excitation and emission wavelengths 
of the imaging agents are shown in Table 3.3. The binding affinities range from single digit 
nanomolar to double-digit nanomolar. The agents had moderate to high plasma protein binding 
and a range from very hydrophilic (negative log D values) to lipophilic molecules (positive log D 
values). The excitation and emission wavelengths were either in the 600-700 nm or 750-800 nm 
range. The agents with wavelengths in the 750-800 range have much higher sensitivity due to the 
lower absorption and scattering of these wavelengths in human tissue.  
Table 3.3 Physicochemical and optical properties of the imaging agents 
 IRDye800CW AF680 Sulfo-Cy7 DDAO Bodipy650 
Molecular 
Weight (Da) 1393 1249 1102 799 939 
Formal 
Charge -4 -3 -2 -2 0 
PPB (%) ± 
S.D. 
91 ± 2 78 ± 3 96.2 ± 0.7 96 ± 2 99.6 ± 0.4 
Log D ± S.D. -3.9 ± 0.5 -3.9 ± 0.5 -2.4 ± 0.2 1.1 ± 0.1 1.9 ± 0.1 
Excitation/ 
Emission(nm) 774/789 679/702 750/773 648/656 646/660 
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The three main criteria used to determine whether or not the imaging agents would work 
well in this technique were high bioavailability, high specific targeting and ideal in vivo optical 
properties (Fig 3.3).  
                                               
Figure 3.3 Venn diagram showing the three main design criteria for developing orally 
available imaging agents 
In order to test the high specific targeting criteria, we imaged all the agents with cells 
with the antigen (αVβ3 +) and cells without the antigen (αVβ3 -). In this experiment, the cells 
without the antigen mimic healthy tissue, which has low to no expression of the antigen that is 
highly expressed on diseased cells, like in the case of cancer. Figure 3.4 shows that cells with the 
antigen have a significant amount of extracellular signal from the imaging agents whereas in the 
antigen negative cells the only imaging agent showing signal is the Bodipy650 agent. The bar 
graph highlights this data by introducing a blocked sample as well, where the antigen positive 
cells are blocked with a non-fluorescent integrin binder but still shows high signal from the 
Bodipy 650 agent. The BODIPY 650 agent has lipophilicity most similar to oral therapeutics 
such as cyclosporine A (logP = 2.92166, F = 30%167), resulting in high non-specific sticking to 
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antigen-negative cells. The failure to meet the high specific targeting criteria led to the 
elimination of the Bodipy650 agent from being tested in vivo.  
 
             
Figure 3.4 In vitro specificity of the imaging agents 
HEK-293 cells with and without the antigen (αVβ3) showing extracellular labeling in the cells 
with the receptor. Cells without the receptor show sticking of the Bodipy650 agent.  Quantitative 
data for non-specific interactions of the imaging agents using antigen negative (αvβ3(-)) and 
blocked controls normalized to the antigen positive cells (αvβ3(+)) show high non-specific signal 
from the Bodipy 650 agent.  
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The non-specific uptake rates of these imaging agents into antigen negative cells were 
measured to give an estimate of the signal expected from healthy tissues in vivo. This data was 
plotted against plasma protein binding which serves as a proxy for lipophilicity of a drug. The 
higher the plasma protein binding, the more lipophilic a drug is and the longer the uptake half 
life of the agent, the lower the signal would be obtained from healthy tissue. The linear 
relationship in the data can serve as a quick way to determine non-specific uptake by conducting 
an in vitro plasma protein binding assay without having to do any cell experiments. Fig. 3.5 
shows this data without the DDAO agent. The reason for this was that while conducting the 
experiment we realized that the fluorescence of the agent decreases significantly when cells 
internalize the agent. On further investigation we found that hydoxy group on the fluorophore 
has a pKa of ~5 which causes the fluorescence to decrease when the in the acidic environment of 
endosomes and lysosomes. Since the DDAO agent loses fluorescence when internalized it did 
not meet the idea in vivo optical properties criteria, it was eliminated from being tested in vivo.  
 
Figure 3.5 Linear trend between non-specific uptake and PPB (proxy for lipophilicity) 
 Based on the criteria shown in fig 3.3, the Bodipy650 and DDAO agents were eliminated 
from consideration. The remaining agents, IRDye800CW, AF680 and Sulfo-Cy7 were tested for 
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oral absorption in black-6 mice. The imaging agents were formulated in water and dosed at 
1mg/kg. The mice were placed in a metabolic cage and their urine was collected for a period of 
24 hours. The fraction of each imaging agent that was absorbed is shown in Fig 3.6.  Overall, the 
oral absorption of these polyanionic conjugates was surprisingly high (Fig. 3.6) and since the 
IRDye800CW agent had the highest amount absorbed, it was selected for testing applications 
like breast cancer and rheumatoid arthritis detection.   
																																														 	
Figure 3.6 Orally absorbed dose (%) 	
3.5 Discussion 
Development of a near-infrared orally available molecular imaging agent is inherently 
challenging, which is likely why, to the best of our knowledge, it has never been reported to date. 
There is an intrinsic dichotomy between physicochemical properties for high oral bioavailability 
and efficient targeting. Orally bioavailable agents are typically lipophilic with a low molecular 
weight to increase absorption. Efficient imaging agents are often hydrophilic with a higher 
molecular weight to reduce non-specific sticking/membrane partitioning and have a large 
binding surface for increased affinity and specificity. Additionally, the bright near-infrared 
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cyanine dyes towards the more ideal 800 nm region of the NIR spectra, due to lower absorption 
in human tissue, are higher in molecular weight. 
To design agents with the highest likelihood of success, we used several target and ligand 
criteria (Fig. 3.2). These design parameters included selecting an extracellular target for easier 
access from the blood, high expression (> 105 receptors/cell), and preferably a significant 
internalization rate (<= 15 hr half-life). The target must have a known small-molecule binder (to 
bypass the de novo screening step) with high affinity (< 10 nM KD), a low molecular weight (< 
500 Da), few heteroatoms to increase the likelihood of intestinal absorption, and preferably a 
known site for fluorophore conjugation with a minimal impact on affinity. Ideally, the agent 
would be selected from a drug candidate that had preliminary oral bioavailability of the targeting 
ligand to avoid first-pass metabolism complications in the liver. While it is likely that not all of 
these criteria are necessary for all orally available probes, it gave the highest chance of success. 
Several agents fit our design criteria, but we chose a small molecule integrin binding 
agent as the targeting ligand. Although monovalent cyclic RGD has proven to be a poor imaging 
agent due to its low affinity168,169, higher affinity variants have demonstrated promising 
results170-172. Integrins, primarily αvβ3, are expressed in a variety of diseases including cancer 
(both tumor cells and activated endothelium) and on macrophages in other inflammatory 
diseases173-175. These integrins are expressed on the cell surface at high levels and are 
internalized within the target cell to residualize the agent97. Several integrin binders have made it 
to phase III clinical trials and are well tolerated at extremely high doses (grams per m2 twice 
weekly for 16 week176). In fact, several have failed due to lack of efficacy177; a negligible 
pharmacological effect is actually ideal for an imaging agent (no on-target toxicity). The 
particular scaffold selected in this work had high bioavailability as a ligand (83% in dogs178) 
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showing no signs of first-pass metabolism. The structure is a relatively simple peptidomimetic 
with available crystallography data179. A known modification site and series of fluorescent 
agents have been successfully developed for small animal imaging as the commercially available 
“Integrisense” series of imaging agents97,180,181. Given the unprecedented nature of the approach, 
this significant background data helped avoid several potential pitfalls for this proof-of-principle 
study. 
Given the lack of precedent in the literature, we set out to generate a series of molecular 
imaging agents that varied in physicochemical properties to study the balance between oral 
bioavailability and targeting efficiency. Having decided on the target and ligand based on our 
earlier mentioned criteria, the ligand was reacted with five different NIR fluorophores such that 
we had a wide range of properties to identify the best suited for an orally available imaging 
agent. The IRDye800CW, AF680 and Sulfo-Cy7 agents, based on sulfated cyanine dyes, are 
hydrophilic in nature and have the highest affinities to the target, making them least likely to 
have off site interactions like sticking to healthy tissue. The DDAO agent has the smallest size 
and is lipophilic, increasing it chances of being orally absorbed. The Bodipy 650 agent has 
lipophilicity similar to a lot of commercially available therapeutics giving it the best chance of 
oral absorption, but also a high likelihood of having non-specific interactions.  
 High bioavailability, ideal in vivo optical properties and specific targeting (Fig 3.3) were 
used to evaluate the imaging agents. In vitro assays to measure the non-specific interactions of 
these agents showed the high amount of sticking of the Bodipy 650 agent to antigen negative 
cells, which did not meet the specific targeting criteria. Although the high lipophilicity of the 
agent makes it a great candidate to be highly orally absorbed, the same lipophilicity also causes it 
to non-specifically stick to antigen negative cells. Therefore, even if a significant fraction of the 
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dose is absorbed, this agent in unlikely to be able to provide good contrast between diseased and 
healthy tissues. The lack of specific targeting led to the elimination of the Bodipy 650 agent.  
While measuring the rates at which all the agents are non-specifically taken up into 
antigen negative cells, we realized that the DDAO agent had poor optical properties. This was 
not evident from the fluorophore optical properties but while running experiments it became 
clear that when the agent was internalized into cells, the fluorescence of the agent dropped 
significantly. This is because one of the hydroxyl group on the fluorophore has a pKa of ~5, 
which impedes its ability to fluoresce brightly in acidic conditions. As agents are internalized 
into cells, they go from endosomes to lysosomes, both of which have an acidic environment 
hindering the DDAO agent’s ability to fluoresce brightly. The	 ideal	 imaging	 agent	 for	 this	technique	needs	to	be	internalized	by	cells	for	up	to	a	few	days,	so	that	the	agent	from	the	rest	body	can	clear	and	increase	the	contrast	between	the	diseased	and	healthy	tissue.	Not	meeting	 the	 ideal	 in	 vivo	 optical	 properties	 criteria	 led	 to	 the	 elimination	 of	 the	 DDAO	agent.		
The remaining three imaging agents were tested for bioavailability and they absorption 
was high considering the molecular weight of the agents (>1000 Da) and the high negative 
charge. Extensive research has been conducted into increasing the oral absorption of 
macromolecules. These investigations include polyanionic agents such as chondroitin sulfate182, 
unfractionated heparins183, anionic dendrimers184-186, and anionic formulations to improve 
absorption of these and other compounds187-192. Fig. 3.7 shows the oral absorption of several 
hydrophilic molecules (clinical data unless otherwise stated) in comparison with the current 
agents193-202. The three agents reported here (black) are within the range of reported clinical and 
animal studies. Alendronate (-2 charge, 249 Da) has lower absorption. Fondaparinux is a charged 
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oligosaccharide with -10 charge and MW = 1728 and low absorption (light blue). When 
formulated to reduce pH and enzymatic degradation, much higher rates of absorption can be 
achieved (hatched light blue). Uncharged PEG (green) has lower absorption with larger 
molecular weight (3350 Da), similar absorption around the same size, and higher absorption with 
lower molecular weight. This is unexpected, since anionic charges typically reduce absorption. 
However, the anions may contribute to improved absorption (while still low compared to 
lipophilic small molecule drugs) since larger anions (chondroitin sulfate, a polydisperse anionic 
polymer, MW = ~21 kDa203 and ardeparin, average MW = 6 kDa, range 2-15 kDa) have been 
reported with similar absorption (yellow). Some evidence suggests that these polyanionic 
molecules can modulate tight junctions to increase paracellular transport191. Polyanions, such as 
heparin, have also been shown to modulate tight junctions in other epithelial tissues such as the 
lung204. 
								 	
Figure 3.7 Oral absorption of anionic molecules 
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In addition to absorption, metabolism and/or excretion within the GI tract and liver (first-
pass metabolism) can greatly impact systemic distribution following oral delivery. The low 
molecular weight heparin, fondaparinux is degraded within the GI tract, likely resulting in the 
higher absorption following formulation as a tablet or nanoparticle193,194. Similarly, charged dyes 
like ICG and some asymmetric cyanine dyes can undergo significant hepatobiliary 
excretion205,206, making these agents unsuitable for oral delivery.  
Lipophilic small molecule drugs can achieve very high oral absorption, and 30% is often 
a goal for pharmaceutical development207. Unlike biologics, which can be expensive to 
manufacture, the cost of small molecule drugs is typically low. The single dose (e.g. once a year 
for screening) compared to daily administration also results in insignificant materials costs, 
which can be compensated by the lack of sterile equipment and medical personnel costs for 
administering intravenous agents. However, variability in absorption is typically a larger issue. 
Because the background tissue autofluorescence is so low in the 800 nm region of the spectrum, 
the sensitivity is very high in this range, providing a low minimum amount of probe. Safety is a 
concern for maximum dose, but similar integrin targeting agents are well-tolerated at extremely 
high doses (grams per m2 twice weekly for 16 weeks176). A more practical concern would be a 
lack of contrast due to high absorption and background signal. This occurs at super-saturating 
doses of the imaging agent, when high plasma concentration increases the background but can no 
longer increase the target signal due to receptor occupancy. For this target, the high expression 
on multiple cell types results in very high doses needed for saturation, yielding an excellent 
‘imaging window’ analogous to a large ‘therapeutic window’ in drug development. 
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3.6 Conclusion 
In conclusion, the large disparity in properties between orally available molecules and 
molecules that have high specificity towards their target, we synthesized a series of imaging 
agents with a wide range in properties. In vitro testing of these agents led to the selection of the 
three hydrophilic agents due to their high affinity to the target, lack of non-specific interactions 
and ideal in vivo optical properties.  The oral absorption of these three agents was measured in 
mice, with IRDye800CW having the highest absorption. To maximize the likelihood of success, 
the IRDye800CW was selected for the detection of breast cancer and rheumatoid arthritis 
following oral delivery of the agent.  	
3.7 Experimental Methods 
Imaging Agent Synthesis 
The agents were generated similar to previous reports163. Briefly, the targeting ligand 
(ChemPartner, Waltham, MA) synthesized as an ester was re-suspended in DMSO at a 
concentration of 300 mg/ ml. The ester group on the integrin binder was hydrolyzed to a 
carboxylic acid by mixing it with 150 µL of ethanol and 7 µL of 1M NaOH per mg of drug with 
continuous stirring overnight. This mixture was then neutralized with 1M HCL and the solvents 
were evaporated.  IRDye 800CW was obtained from LI-COR (Lincoln, NE)), Alexa Fluor 680, 
BODIPY 650/665-X and CellTrace Far Red DDAO were obtained from Life Technologies 
(Carlsbad, CA), and Sulfo-Cyanine7 was obtained from Lumiprobe (Hallandale Beach, FL) in 
the NHS ester form. The hydrolyzed integrin binder was reacted with the fluorescent dyes in a 
2:1 molar ratio in the presence of 2 µL of triethylamine per mg of drug. The reaction was run 
overnight and purified using a preparative scale Luna C18(2) column (Phenomenex; Torrance, 
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CA) on a Shimadzu reverse phase HPLC. Full purification methods are provided in the 
supplementary data in Table S6. The purified products were run on a MALDI-TOF (High 
affinity IRDye800CW agent: m/z calculated 1397, found 1396; AF680 agent: m/z calculated 
1253, found 1253; Sulfo-cyanine7 agent: m/z calculated 1103, found 1104; DDAO agent: m/z 
calculated 800, found 798; Bodipy 650 agent: m/z calculated 939, found 940; low affinity IRDye 
800CW agent: m/z calculated 1397, found 1399). The purities of these agents (254 nm) were 
measured on HPLC (High affinity IRDye800CW agent: 95% (99.9% fluorescence purity); 
AF680 agent: 96.5%; Sulfo-cyanine7 agent: 88% (99.4% fluorescence purity); DDAO agent: 
92%; Bodipy 650 agent: 87.5% (99.2% fluorescence purity); low affinity IRDye 800CW agent: 
97.4% (99.9% fluorescence purity)). 
Table 3.4 Purification methods and MALDI results 
 Mobile Phase 
HPLC 
Method 
Retention 
Time 
Expected 
MW 
Observed 
MW 
IRDy800CW 
A: 25mM 
TEAA in 
water 
B: MeCN 
25% B 0-6 
min, 25-45% 
B 6-24 min 
14 min 1397.682 1395.922 
AF680 
A: 0.1% TFA 
in water 
B: 0.1% TFA 
in MeCN 
5-30% B 0-12 
min, 
30-60% B 12-
16min 
13.25 min 1253.351 1253.314 
Sulfo-
Cyanine7 
A: 25mM 
TEAA in 
water 
B: MeCN 
15-60% B 0-
20 min 15 min 1103.405 1104.727 
DDAO 
A: 0.1% TFA 
in water 
B: 0.1% TFA 
in MeCN 
20-95% B 0-
15 min 9.75 min 800.8 796.8 
Bodipy 650 
A: 0.1% TFA 
in water 
B: 0.1% TFA 
in MeCN 
20-95% B 0-
15 min, 
95% B Hold 
15-16 min 
11.5 min 938.9 940.1 
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 Cell Lines 
All reagents mentioned below were obtained from Life Technologies (Carlsbad, CA) 
unless specified otherwise. MDA-MB-231 and HEK-293 cells were purchased from ATCC 
(Manassas, VA) and grown in DMEM with 10% FBS and 1% Penicillin-Streptomycin 
(supplemented with 1% L-Glutamine for MDA-MB-231). HEK-293 cells, which express 
endogenous αv but not β3208 were transfected with the β3 integrin subunit (Addgene plasmid 
27289) to generate an αvβ3 positive line. Cells were transfected with Lipofectamine 2000 
according to the manufacturer’s instructions and selected with 1 mg/mL G418 in the media.   
Characterization (logD, PPB, affinity) 
The binding affinity of all agents was measured using the transfected HEK-293 cells. The 
cells were harvested and incubated in triplicate with varying concentrations of the agents in 
suspension for 3 hours on ice. The cells were washed with PBS and run on an Attune acoustic 
focusing cytometer to quantify the fluorescence. Dissociation constants for each of the agents 
were determined by analyzing the data on Prism (GraphPad Software; La Jolla, CA). The large 
amount of non-specific signal generated from receptor-negative cells for the lipophilic BODIPY-
650 agent was subtracted from the receptor positive cell line signal for an accurate measurement 
of the specific receptor dissociation constant. 
Transfected and untransfected HEK-293 cells were plated on chamber slides and allowed 
to attach overnight. The cells were incubated with either 10 nM of the agent (IRDye 800CW and 
AlexaFluor 680) or 50nM (Bodipy 650/665-X, DDAO, and Sulfo-Cyanine7) for 25 minutes at 
37 °C and washed with fresh media. The cells were then imaged on an Olympus FV1200 
confocal microscope using the 405, 635, and 748 nm lasers.  
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Plasma protein binding (PPB) of the agents was measured using a Rapid Equilibrium 
Dialysis (Thermo Scientific; Rockford, IL) plate according to the manufacturer’s instructions. 
Mouse plasma (Innovative Research; Novi, MI; Cat. No. C57BL6) was mixed with 1 µM of the 
agents. After equilibration, the buffer in each chamber was adjusted to 50% mouse plasma in 
PBS to eliminate effects of protein binding on fluorescence. The signal was measured using an 
Odyssey CLx (LI-COR; Lincoln, NE). 
The logD7.4 for all the agents was measured using a protocol adapted from Miller et al209. 
The agents were prepared at a concentration of 5-50 µM in octanol-saturated phosphate buffered 
saline (PBS, pH 7.4). 200 µL of this solution was mixed with 200 µL of PBS-saturated octanol. 
The mixture was stirred at 700 rpm for 24 hours. For lipophilic agents, the aqueous phase 
concentration was directly measured using fluorescence with the mass balance yielding the logD. 
Hydrophilic compounds with minimal loss in the aqueous phase were measured using a second 
extraction step. After the first equilibration, 150 µL of the octanol was mixed with 50 µL of fresh 
octanol-saturated PBS to extract the probe in the octanol phase and measure the aqueous 
fluorescence. During the fluorescence read-out, the samples and calibration curves were diluted 
in 0.5% PBS-BSA to minimize precipitation and sticking to the vessel surface.  
 
In Vivo Oral Absorption  
Eight week old C57BL/6 female mice (n = 3-4 per cohort) were used to measure the oral 
absorption of the imaging agents. All experiments involving mice were conducted in compliance 
with the University of Michigan University Institutional Animal Care and Use Committee 
(IACUC). The mice were fasted for 4-6 hours and then dosed with 1 mg/kg of the imaging agent 
via oral gavage and placed in a metabolic cage for a period of 24 hours. Urine was collected 
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from these cages at the end of 24 hours. The urine was diluted 10 fold in 0.1% PBS-BSA to 
prevent the agent from sticking to vessel surfaces. This was then measured on an Odyssey CLx 
to determine the amount of fluorescent agent present in the urine. This was quantified using a 
calibration curve of each agent.  	  
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Chapter 4: Breast Cancer Screening in an Orthotopic Mouse 
Model with an Orally Available Near Infrared Molecular 
Imaging Agent 
4.1 Publication Information 
Bhatnagar S, Verma KD, Hu Y, Khera E, Priluck A, Smith DE, Thurber GM 2018. Oral 
Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic 
Mouse Model for Breast Cancer Screening. Molecular pharmaceutics  15(5):1746-1754.  
Modifications have been made to the published document to adapt the content to this 
dissertation. 
4.2 Abstract 
Molecular imaging is ideal for disease screening by providing precise spatial information 
of disease-associated biomarkers, something neither blood tests nor anatomical imaging can 
achieve. However, high costs and risks of ionizing radiation for several molecular imaging 
modalities have so far prevented a feasible and scalable approach for screening109. Clinical 
studies have demonstrated the ability to detect breast tumors using non-specific probes such as 
indocyanine green151,210, but the lack of molecular information and required intravenous contrast 
agent does not provide a significant benefit over current non-invasive imaging techniques. Here 
we demonstrate that negatively charged sulfate groups, commonly used to improve solubility of 
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near-infrared fluorophores, enable sufficient oral absorption and targeting of fluorescent 
molecular imaging agents for completely non-invasive detection of diseased tissue such as breast 
cancer. These functional groups improve the pharmacokinetic properties of affinity ligands to 
achieve targeting efficiencies compatible with clinical imaging devices using safe, non-ionizing 
radiation (near infrared light). Together, this enables the development of a ‘disease screening 
pill’ capable of systemic absorption, target binding, background clearance, and imaging at 
clinically relevant depths for breast cancer screening. This approach should be adaptable to other 
diseases and molecular targets for use as a new class of disease screening agents.  
4.3 Background 
Molecular imaging has the potential to provide significant improvement in breast cancer 
screening. While therapy has been rapidly advancing towards molecular characterization, 
screening relies on anatomical differences that have several limitations109. These include the lack 
of molecular information to identify aggressive tumors versus those that pose no mortality risk 
(over-diagnosed tumors)211,212 and the lack of contrast in dense breast tissue that carries 
increased risk, particularly prevalent in younger women213,214. These limitations have led to an 
estimated $4 billion being overspent on false-positives and overdiagnosis215. The shortcomings 
in sensitivity and specificity of anatomical imaging have motivated research in new imaging and 
systemic detection modalities106,216, including near-infrared imaging217,218. Current scanners are 
capable of imaging tumors less than 2 cm in diameter that are imbedded deep in breast tissue at 
the contrast levels we report here219,220, and further improvements in complementary 
technologies, such as photoacoustic imaging, are likely to push the detection limits even 
smaller221.  
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	 Many integrin-targeted imaging agents are currently being investigated in clinical trials 
(e.g. 8 RGD-based probes reviewed recently222). The high level of expression on multiple 
distinct cell types, including stromal tissue, is advantageous for early screening because of an 
anticipated robust detection sensitivity (e.g. all tumors will require neovasculature beyond a 
certain size, immune cell infiltration is associated with greater risk of recurrence even with small 
lesions like DCIS223). The typically high level of expression on these cells types also increases 
the dose-window for imaging by lowering the chances of receptor saturation (which would 
reduce contrast).     
 
Table 4.1 Integrin expression levels on various cell types 
 Expression level (receptors/cell) Refs 
Activated endothelium 1.7x105 224 
Macrophages 2x105 225 
Tumor cells ~5-10x104 226,227 
  
In addition to detection sensitivity, the tumor expression of αVβ3 integrin is associated 
with more aggressive tumors due to increased angiogenesis and more aggressive forms of 
DCIS228. This is particularly poignant as analyses of large data sets indicate that the current use 
of mammography is over-diagnosing and treating women229,230. The over-diagnosis of women 
with breast lesions is particularly problematic with some estimates indicating a cost of $4 billion 
per year215. The rate of overdiagnosis can be reduced with the right selection criteria, such as 
high grade DCIS in younger women231. Molecular imaging agents have the potential to better 
differentiate aggressive lesions versus benign conditions, and these promise will have to be 
tested in the clinic. For example, microvessel density (endothelial targeted cells) is higher in 
DCIS with a high proliferative index, HER2 expression, and Comedo-type lesions228. There is 
very low macrophage infiltration (macrophage-targeted cells) in normal breast and benign 
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proliferative disease but this is elevated in DCIS and even higher with invasive carcinoma232. 
The presence of these markers early in breast cancer development is critical for detecting early 
stage cancers and high-risk DCIS, which is ideal for initial screening purposes.  
 A significant benefit from using molecular imaging agents is expected to be the ability to 
detect aggressive breast cancers in younger women and/or women with dense breast tissue. 
Women with dense breast tissue have a markedly increased risk for invasive breast cancer233 and 
have a higher risk of dying from their cancer (e.g. following DCIS234). Because the detection is 
based on fluorescence from a molecularly targeted agent (and not tissue density differences), the 
sensitivity and specificity is not expected to be highly dependent on breast tissue density. Note 
that for non-specific NIR probes, differences in uptake have been noted from tissue differences 
alone, motivating a targeted probe approach150. Additionally, the propagation of NIR is similar 
between breast tissue types235 This benefit has been demonstrated with radiolabeled integrin 
targeting agents in the clinic, where sensitivity to lesions was higher in women with dense breast 
tissue236. The utility of the approach will need to be verified in clinical trials, but it may find a 
role in screening younger women who do not benefit from mammography and/or used in 
conjunction with mammography where sensitivity and specificity can be greatly improved with 
dual modalities236. 
As mentioned in Chapter 3, the route of administration of a molecular imaging agent for 
screening purposes is critical for a feasible and scalable approach, where the target rates for 
mammography are already difficult to achieve237. Oral delivery is safer, less expensive and likely 
to have a higher compliance compared to other routes of delivery. Therefore, in this study we 
orally deliver an integrin binding agent in orthotopic breast cancer mouse models to show the 
applicability of the technique in the detection of breast cancer.  
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4.4 Results 
High uptake and specificity of imaging agent in breast cancer 
Using an orthotopic xenograft model of breast cancer (MDA-MB-231 cells injected in the 
mammary fat pad), mice were dosed with 5 mg/kg of the IRDye800CW by oral gavage and 
imaged at 6, 24, and 48 hours post injection (Fig. 4.1). The tumors had significant uptake by 6 
hours, and the intestinal signal cleared at the later time points to yield high contrast by 24 and 48 
hours (tumor to background ratios of ~4 at 48 hours).  
 
 6 hours 24 hours 48 hours 
Measured Intensity 
(×108) 1.5 ± 0.3 1.6 ± 0.3 1.3 ± 0.3 
TBR 1.7 ± 0.1 2.8 ± 0.2 3.9 ± 0.7 
Figure 4.1 Whole animal fluorescent images, intensity and TBR for the IRDye800CW agent 
The image intensity shows that the amount of the probe in the tumor stays relatively 
constant over a period of 48 hours owing to the residualizing nature of the NIR fluorophore238.  
To demonstrate specificity, we used a low-affinity stereosiomer since the two most common 
71		
techniques, blocking specific uptake or using an antigen negative tumor, were not feasible. The 
structures for both the agents are shown in figure 4.2.  
 
													 	
Figure 4.2 Structure for the IRDye800CW agent and its stereoisomer with the chiral 
carbon highlighted in the red circle. 
 The IRDye800CW agent stereoisomer has an affinity to integrin, which is an 
order of magnitude worse than the affinity of the IRDye800CW agent. The lower affinity would 
theoretically lead to lower uptake in the tumors, which is exactly what Fig. 4.3 shows indicating 
that the IRDye800CW agent is taken up through specific interactions with the integrin receptor. 
This is important as we are trying to obtain molecular information about the tumor. The whole 
animal fluorescence intensity and biodistribution showed dramatically lower uptake for the 
stereoisomer. Biodistribution data at 48 hours (Fig. 4.4) correlated well with the whole animal 
images (Fig. 4.1 and 4.3) showing that the amount of agent in the tumor was significantly higher 
in the tumor for the IRDye800CW agent compared to the stereoisomer. 
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 6 hours 24 hours 48 hours 
Measured Intensity 
(×108) 0.78 ± 0.08 0.3 ± 0.1 0.22 ± 0.7 
TBR 1.1 ± 0.4 1.8 ± 0.2 1.8 ± 0.2 
 
Figure 4.3 Whole animal fluorescent images, intensity and TBR for the IRDye800CW agent 
stereoisomer 	
   
	
Figure 4.4 Biodistribution data of the IRdye800CW agent and stereoisomer at 48 hours 
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The IRDye800CW agent panel in Fig 4.4 shows signal from the orally delivered agent, 
Mac3 panel labels the macrophages in the tissue slice, the CD31 labels all blood vessels, integrin 
labels all available αVβ3, and Hoechst labels the nuclei of all cells. The IRDye800CW agent 
image is blurry as it was taken at a different resolution that the other images. The signal from the 
agent was diffuse throughout tissue requiring a macroscopic image of the tissue. All the other 
labels were ex vivo to identify the different cell types in the slice. Integrins are expressed at high 
levels on breast cancer cells, tumor associated macrophages, and neovasculature, providing 
robust detection by diversifying the cellular targets. The rapid tumor penetration of this low 
molecular weight compound and intermixed cell types in this model47 resulted in relatively 
uniform signal throughout the tumor with potentially higher uptake by tumor associated 
macrophages shown by the overlap of the first two panels (Fig. 4.5).   
 
Figure 4.5 Histology of tumor tissue with the IRDye800CW agent and other ex vivo stains 
Macroscopic images of tumor histology slide taken on an Odyssey CLx (IRDye800CWagent) 
and Olympus FV1200 confocal microscope (other channels). The orally delivered agent shows a 
diffuse pattern in tumors compared to the negative control (not shown). The intensity appears to 
be slightly higher in regions with higher macrophage density versus tumor cells or blood vessels 
(CD31). The slides were labeled with the AF680 agent ex vivo (integrin) and stained with 
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Hoechst 33342 to show the presence of cells and integrin throughout the tissue. Scale Bar = 500 
µm. 
 
4.5 Discussion 
Oral delivery and non-invasive detection of near-infrared fluorescent molecular imaging 
agents has significant advantages over other screening modalities including low cost, increased 
safety, portability, and non-invasive molecular imaging results. They also have the promise to 
provide spatial and molecular information to a physician using a method less invasive than a 
blood test. Particular advantages over intravenous delivery of these agents include a lower risk of 
anaphylaxis due to oral, which is an important consideration for screening a healthy population, 
needle-free and pain-free self-administration for improved patient compliance, and the potential 
application in resource-limited settings without the need for medical facilities and sterile reagents 
The IRDye800CW agent gave excellent contrast in the orthotopic breast cancer model. 
To better understand the temporal imaging window, mice were imaged at 6, 24 and 48 hours 
after oral gavage. Similar to intravenously delivered agents, the signal intensity was highest at 
earlier times, but the TBR increased at longer times (Fig. 4.1). Forty-eight hours yielded TBR 
values averaging 4 (n=3 mice). Mice were sacrificed at this time to measure the biodistribution 
with 2.5% orally absorbed dose per gram remaining in the tumor two days after oral gavage. The 
optimal imaging time, days after delivery, exemplifies one of the strengths of this approach. Oral 
delivery, in contrast to intravenous injection, does not require multiple visits for agent delivery 
and a return visit for imaging. 
One of the main goals of this technique is to provide molecular information about the 
tumor along with detection, which is something that mammography cannot provide. Thus, to 
make sure that we are obtaining molecular information we need to make sure that the imaging 
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agent is being taken up specifically in the tumor through interaction with the αVβ3 receptor. In 
order to test this specific uptake in the tumor, a stereoisomer of the ligand was conjugated with 
IRDye800CW to create a low affinity imaging agent. The affinity of the IRDye800CW agent is 
5.1nM for αVβ3 while it is 40nM for the stereoisomer. This allowed us to use the stereoisomer as 
a negative control, while still maintaining all the properties of the imaging agent other than 
affinity. Traditional negative controls like blocking or antigen negative controls were not feasible 
for these in vivo experiments. Since the imaging agent is orally absorbed over the period of 
several hours (Fig 4.6), it would require an impractical amount of non-fluorescent ligand to 
completely block all the integrins within the tumor. Antigen negative controls would not work 
either since αVβ3	is expressed on activated macrophages and neovasculature, which are present in 
almost all tumor types. The controls showed that the stereoisomer was taken up significantly 
lower in the tumor and other organs (Fig. 4.4) in spite of having similar oral absorption (Fig. 
4.6). Healthy tissue expresses αVβ3 at low levels explaining the low uptake in healthy tissues. 
This control clearly shows that the imaging agent is being taken up in the tumor specifically and 
the lack of the control uptake was due to its lower affinity towards the target.  
	
Figure 4.6 Plasma clearance following oral administration 
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 Mammography is the current gold-standard for breast cancer screening239 but the large 
number of false positives and negatives215,240,241 could be improved through more specific and 
sensitive imaging, particularly for younger women with denser tissue242. Extensive work on NIR 
optical tomography128 and fluorescence imaging151 has demonstrated excellent tissue penetration 
of NIR light in breast tissue243. αvβ3 is upregulated on both activated endothelium and breast 
cancer cells244 and expression correlates with a more aggressive phenotype and bone 
metastasis245,246. Ultimately, this technique may pair well with clinically used ultrasound of the 
breast247. Analogous to PET-CT, NIR fluorescence would provide molecular information and 
ultrasound would generate anatomical reference in an inexpensive, hand-held format248,249 for 
enhancing the selectivity and specificity of breast cancer detection. 
Many integrin-targeted imaging agents are currently being investigated in clinical trials 
(e.g. 8 RGD-based probes reviewed recently222). The high level of expression on multiple 
distinct cell types, including stromal tissue, is advantageous for early screening because of an 
anticipated more robust detection sensitivity (e.g. all tumors will require neovasculature beyond 
a certain size, immune cell infiltration is associated with greater risk of recurrence even with 
small lesions like DCIS223). The typically high level of expression on these cells types also 
increases the dose-window for imaging by lowering the chances of receptor saturation (which 
would reduce contrast).     
In addition to detection sensitivity, the tumor expression of αVβ3 integrin is associated 
with more aggressive tumors due to increased angiogenesis and more aggressive forms of 
DCIS228. This is particularly poignant as analyses of large data sets indicate that the current use 
of mammography is over-diagnosing and treating women229,230. Molecular imaging agents have 
the potential to better differentiate aggressive lesions versus benign conditions, and reduce the 
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rate of overdiagnosis through better detection of at-risk tumors, such as high grade DCIS in 
younger women231. For example, microvessel density (endothelial targeted cells) is higher in 
DCIS with a high proliferative index, HER2 expression, and Comedo-type lesions228. There is 
very low macrophage infiltration (macrophage-targeted cells) in normal breast and benign 
proliferative disease but this is elevated in DCIS and even higher with invasive carcinoma232. 
The presence of these markers early in breast cancer development is critical for detecting early 
stage cancers and high-risk DCIS, which is ideal for initial screening purposes.  
Several clinical studies have demonstrated the feasibility of imaging breast tumors deep 
within breast tissue. These studies have primarily used indocyanine green (ICG), which is a non-
targeted contrast agent that is approved by the FDA. 
 
Table 4.2 Clinical breast cancer imaging studies 
 Tumor size Contrast Ref 
ICG ~1 cm (absorption) 218 
ICG 1.5, 1.6, and 2.5 cm 3.5 to 5.5 210 
ICG 1.6 and 1.1 cm 1.5 to 1.8 250 
Omocyanine 2.9, 1.8, 2.4, 7.4, 3.4 cm 1.8 to 2.8 150 
ICG 2.5 cm (mean), range 1.1 to 5.2 cm 0.25 to 0.64 151 
 
Probing breast tissue using light (diaphanography) dates back to the 1920’s but made 
substantial advances in the late 1990’s and early 2000’s due to improvements in imaging 
equipment and tomographic techniques251. Corlu et al. was the first to publish fluorescence 
imaging of human breast tumors using ICG. The fluorescence imaging gave the best contrast, 
and other studies have indicated that fluorescence is better than absorption with low background 
concentrations220. Despite the promising results found in several trials, untargeted contrast agents 
do not perform better than mammography alone252, and there is a strong need for targeted 
contrast agents150. 
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Many additional studies have tested the limits of detection both theoretically and with 
optical phantoms. Tumors less than 2 cm219 can be detected in the contrast ranges achieved here 
in mice, and the absolute concentrations of IRDye800CW are much higher than those detected 
using a clinical breast imaging system253, indicating the contrast achieved with these orally 
delivered agents is suitable for clinical detection using diffuse optical tomography, as used in the 
studies with Omocyanine from Table 4.2. 
A significant benefit from molecular imaging is the ability to detect aggressive breast 
cancers in younger women and/or women with dense breast tissue. Women with dense breast 
tissue have a markedly increased risk for invasive breast cancer233 and have a higher risk of 
dying from their cancer (e.g. following DCIS234). Because the detection is based on fluorescence 
from a molecularly targeted probe (and not tissue density differences), the sensitivity and 
specificity is not expected to be highly dependent on breast tissue density235. (Note that for non-
specific NIR probes, differences in uptake have been noted from tissue differences alone, 
motivating a targeted probe approach150.) This benefit has been demonstrated with radiolabeled 
integrin targeting agents in the clinic, where sensitivity to lesions was higher in women with 
dense breast tissue236. The utility of the approach will need to be verified in clinical trials, but it 
may find a role in screening younger women who do not benefit from mammography and/or 
used in conjunction with mammography where sensitivity and specificity can be greatly 
improved with dual modalities236. 
Results from this study demonstrate that molecules can overcome the significant physical 
and kinetic barriers for sufficient oral delivery and targeting of molecular imaging agents. 
Hydrophilic molecules, particularly anionic drugs, have low oral bioavailability and high patient-
to-patient variability in absorption. Rapid hepatic clearance of near-infrared dyes like 
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indocyanine green could further lower systemic absorption through first-pass extraction205. 
However, several polyanionic molecules have shown measurable absorption following oral 
delivery183,254. Oral heparin, another sulfonated macromolecule, is susceptible to stomach acid 
degradation, but with proper formulation, absorption in animal models ranges from 3% to 
38%193,194,255,256. A Phase III clinical trial demonstrated effective absorption 255. Similarly, 
negatively charged chondroitin sulfate has measurable absorption in humans201, as does 
polyanionic dendrimers in animal models186. 
Unlike therapeutics that often have a narrow window between toxicity and efficacy (and 
higher material cost for continual daily administration), the absorption of imaging agents is more 
tolerable to patient-to-patient variability. The upper limit here is target saturation (where higher 
doses would lower contrast) since even gram doses of anti-integrins are well-tolerated176, and the 
lower bound is image noise from autofluorescence. The optimal 800 nm imaging channel and 
high target expression provide a large window for achieving efficient contrast. 
Besides total absorption, there are significant hurdles in targeting due to the slower 
absorption rate following oral delivery compared to intravenous delivery. A dissociation rate of 
days at 37°C would be required to maintain significant signal until the probe is fully absorbed 
and cleared from background tissue. However, by selecting internalizing targets, the anionic 
charge can aid in trapping the dye within cells for days238. Despite the long time period between 
delivery and imaging, this is still favorable from a patient compliance standpoint, since 
intravenous delivery of low molecular weight agents requires a minimum of hours to develop 
contrast. This would necessitate extended or multiple clinical visits – the first to receive an 
intravenous dose and monitoring for adverse reactions followed by an imaging visit several 
hours to days later. While this may not be an impediment for life-saving surgery with 
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intraoperative imaging139, it could have a major impact on patient compliance in screening large 
healthy populations. Because material costs for small molecules are often low (e.g. $1 per dose 
for small molecule drugs147), the associated costs of medical personnel and sterile intravenous 
delivery would likely be higher than any cost savings from improved bioavailability from more 
invasive routes. 
In the current approach, contrary to radiolabeled probes163, some plasma protein binding 
is beneficial by slowing clearance relative to absorption, increasing the plasma concentration, 
and improving target signal relative to background autofluorescence (Fig. 4.6). Therefore, the 
plasma protein binding mediated by the high anionic charge also plays a role in enabling orally 
delivered molecular imaging agents.  
There are several current limitations and areas for improvement with this approach. First, 
the 2.5% absorbed dose results in variability between mice. While this variability does not 
impact the contrast significantly since both tumor signal and background are approximately 
linear with absorbed dose, mice at the very low end of the absorption profile risk having 
autofluorescence lower the contrast to noise ratio. Improved formulation could increase the 
absorption and lower the variability, thereby reducing the dose needed. Second, clinical trials 
with intravenously delivered non-specific contrast agents have highlighted the difficulty in 
imaging tumors in the breast near the chest wall, similar to mammography. Improvements in 
alternative detection methods, such as optoacoustic imaging, may provide better detection in this 
region. Finally, although the current probe provides molecular information, which is an 
improvement over anatomical images, a single biomarker will not be able to differentiate all 
tumor types. Additional biomarkers, e.g. from dual-channel imaging at a second NIR wavelength 
with a different probe, could significantly increase the diagnostic specificity. The use of 
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negatively charged probes should be adaptable to other small molecule targeting ligands against 
different surface markers.  
 
4.6 Conclusion 
In conclusion, the high negative charge density on the IRDye800CW agent enabled 
sufficient absorption, reduced non-specific uptake, facilitated targeting by extending the 
clearance half-life, and increased retention through cellular trapping to yield efficient targeting 
contrast in a small animal model of breast cancer for detection at clinically relevant depths. It 
was able to provide a TBR of 4 at 48 hours post administration of the imaging agent in 
comparison with the stereoisomer, which only had a TBR of 1.8, highlighting the efficient 
uptake through specific interactions with the αVβ3 receptor. To our knowledge, this is the first 
demonstration of a disease screening approach using oral administration of a molecular imaging 
agent, and these mechanisms should be applicable to additional probes and disease targets for 
developing a series of molecular imaging agents for non-invasive screening. 	
4.7 Experimental Methods 
In Vivo Imaging 
MDA MB 231 cells were used for tumor xenografts in nude mice (Jackson Laboratory; 
Bar Harbor, ME). The cells were harvested using Trypsin-EDTA (0.05%), re-suspended in 
Matrigel (Corning; Corning, NY) at a concentration of 5 million cells/50 µL. Mice were 
anesthetized using isoflurane at 2% and 1 L/min oxygen and the cells were injected 
subcutaneously by the first nipple in the mammary fat pad to avoid fluorescence signal from the 
gut when imaging. The tumors were imaged once the longest axis of the tumor reached 7-10 mm. 
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Tumor-bearing mice were anesthetized and imaged in an IVIS Spectrum (Perkin Elmer; 
Waltham, MA) at 6, 24 and 48 hours post injection.  
Tumor-bearing mice were fed AIN-93M non-fluorescent chow (Harlan; Indianapolis, IN; 
Cat. No. TD.94048) for 2 weeks before oral gavage and were fasted for 4-6 hours pre-oral 
administration. Mice (n = 3 per cohort) were imaged on an IVIS Spectrum (Perkin Elmer; 
Waltham, MA) at 6, 24, and 48 hours after administration of the agent, and the LivingImage 
software (Perkin Elmer; Waltham,MA) was used to measure the signal intensity in the tumor and 
TBR. The biodistribution protocol is adapted from Oliviera et al257. In short, the mice were 
euthanized at 48 hours post administration and all their organs were resected. The organs (part of 
the tumor was frozen in OCT for histology slides) were minced with a razor blade and weighed. 
They were placed in Eppendorf tubes and digested using a collagenase (Worthington 
Biochemical; Lakewood, NJ; Cat. No. CLS-4) solution (5 mg/ ml) in RIPA buffer (Boston 
BioProducts; Ashland, MA) at 37°C for 20 minutes. The organs were sonicated, digested for 30 
minutes at 37°C using a 50:50 trypsin and RIPA buffer solution and sonicated again. The 
resulting mixture was plated in a dilution series in a black walled 96-well plate and imaged using 
the Odyssey CLx. Absolute quantification was obtained by comparison with a calibration curve. 
The uptake values were normalized to the average amount of probe that reached the systemic 
circulation (absorbed dose) per gram of tissue (versus injected dose per gram (%ID/g) used for 
intraveneous delivery). 
Histology 
Frozen blocks of the tumor in OCT were sectioned into 14 uM slices on a cryostat. The 
slices were first imaged on the Odyssey CLx in the presence of PBS to prevent the tissue from 
drying out. This slice was then stained ex-vivo with Hoechst 33342 (Thermo Fisher Scientific; 
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Cat. No.H3570), the AF680 conjugated probe (due to its higher affinity), Cetuximab (Bristol-
Myers Squibb, Princeton, New Jersey) labeled AF750, anti-Mac3 antibody (BD Biosciences, San 
Jose, CA: Cat. No. 553322) labeled AF555 and anti-CD31 (BioLegends, San Diego, CA; Cat. 
No. 102402) labeled AF488. These slides were then washed in PBS and imaged on an Olympus 
FV1200 confocal microscope equipped with 405, 488,543, 633 and 748 nm laser lines.  
The integrin image in Fig. 4 was post processed to remove stitching artifacts. We used 
the ImageJ FFT bandpass filter, suppressing horizontal and vertical lines with a cut-off of 2500 
pixels and 0 pixels with a 5% tolerance.   
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Chapter 5: Orally Available Near Infrared Imaging Agents 
for the Detection of Rheumatoid Arthritis 
5.1 Publication Information 
Bhatnagar S, Khera E, Liao J, Eniola V, Hu Y, Smith DE, Thurber GM. Self-Administration of 
Near-Infrared Fluorescent Imaging Agents for the Early Detection of Rheumatoid Arthritis. 
Submitted. 
 Modifications have been made to the published document to adapt the content to 
this dissertation. 
5.2 Abstract 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes 
irreversible damage of the joints. However, effective drugs exist that can stop disease 
progression, and there is intense interest in early detection and treatment to improve patient 
outcomes. Imaging has the potential for early detection, but current methods lack sensitivity 
and/or are time-consuming and expensive. In this study, we examined self-administration of 
molecular imaging agents in the form of sub-cutaneous and oral delivery of an integrin binding 
near-infrared (NIR) fluorescent imaging agent to increase patient compliance for regular 
screening of RA. This technique, in comparison to current imaging modalities, has relatively low 
cost, high safety profile with the use of non-ionizing radiation, the ability to provide spatial and 
molecular information and is minimally invasive. This study shows significant uptake of an 
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IRdye800CW agent in inflamed joints of a CAIA mouse model compared to healthy joints, 
irrespective of the method of administration. The results were extrapolated to clinical depths 
using a 3D COMSOL model of NIR fluorescence imaging in a human hand. With target to 
background concentration ratios greater than 5.5, which is achieved in the mouse model, these 
probes have the potential to identify arthritic joints following oral delivery at clinically relevant 
depths. 
5.3 Background 
Rheumatoid arthritis (RA) is a chronic joint disease marked by pain and inflammation 258 
that affects 0.5% to 1% of the population worldwide 259. Despite several existing treatments and 
recent advances in disease therapy, remission rates and morbidity remain a critical concern for 
RA patients 260. Given the irreversible damage caused by joint inflammation and prevalence of 
effective disease modifying drugs, it is widely viewed that earlier treatment is needed for more 
effective management of RA. There is also some evidence that early intervention, specifically in 
cases of RA, has the potential for curative treatment261. However, current blood tests do not have 
adequate sensitivity and specificity for accurate diagnosis, and these tests do not provide insight 
into local joint conditions. Therefore, new quantitative diagnostic methods are needed to identify 
the pathology at an early stage to reduce disease morbidity 262. An inflamed synovial membrane 
is one of the earliest indications of the onset of RA 263. Conventional imaging methods such as 
ultrasonography, provide a valid assessment of synovitis 264 but lack sensitivity for early arthritis 
signs 265. Contrast enhanced magnetic resonance imaging (MRI), with its excellent soft tissue 
contrast, is able to provide details about inflammation within the joints and predict the disease 
progression at an early stage 266, but this method is time-consuming and expensive for routine 
screening applications 267. 
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Optical molecular imaging is considered a promising alternative method for early stage 
RA detection. It has the advantage of providing specific molecular information without the use 
of ionizing radiation used in PET and SPECT molecular imaging methods. There have been 
several reported correlations between the severity of joint inflammation and fluorescence 
intensities from molecular probes 134,268,269. Indocyanine green (ICG), a non-specific dye that 
binds to plasma proteins, has been studied in a few reports since it is the only clinically approved 
near-infrared (NIR) dye 270. Although ICG has been reported to differentiate RA joints from 
healthy joints during later stages of the disease 271, detection at the earliest stages, ideally 
subclinical inflammation for screening purposes, remains challenging and unrealized 134,135,272.  
In order to make early detection of RA feasible using optical molecular imaging, it 
requires a route of administration that is safe, inexpensive, and convenient for patients (to 
improve compliance). Self-administration methods like subcutaneous injection (SC) and oral 
delivery (PO) are ideal for screening large portions of the population as it saves time, medical 
personnel costs, and are preferred by patients 148,149. Intravenous delivery, the most common 
form of delivery of imaging agents, has a higher risk of adverse reactions 144,145. While these 
absolute values are low, the risk in screening large numbers of patients, particularly in a healthy 
population, sets a high bar. Additionally, even the fastest clearing agents require imaging to take 
place several hours post administration to allow for the imaging agent to clear from the body, 
which results in multiple or extended visits to the clinic. These visits can increase cost from 
health care professional time required to dose the patients in a sterile manner and monitor the 
patients in case of adverse events. Self-administration of these imaging agents would allow for a 
single visit to the clinic for imaging thereby mitigating the costs of screening.  
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We developed an integrin (αVβ3) binding imaging agent that has been shown to 
efficiently target breast cancer in an orthotopic mouse model via oral administration (Chapter 4). 
We hypothesized that due to the high expression of avβ3 integrins on activated macrophages and 
the high macrophage infiltration in RA, we could use methods of self-administration to detect 
inflammation of the joints in arthritis. These imaging agents are comprised of a targeting ligand 
that binds integrin of the form avβ3 97 conjugated to a negatively charged NIR fluorophore. Given 
the different transport rates in the synovial tissue compared to tumors, we tested two methods of 
self-administration: subcutaneous and oral delivery. In contrast to breast cancer, where a 
significant amount of NIR clinical imaging has been conducted to show the feasibility of 
imaging tumors imbedded deep within the breast tissue (Table 4.2), much of the clinical NIR 
imaging in RA has been done with non-targeted agents such as ICG. In order to efficiently test 
the translatability of these molecular imaging agents to humans at clinically relevant length 
scales, this study employed a three dimensional (3D) simulation utilizing previously validated 
models of diffuse light fluorescence imaging 273,274 to determine the necessary concentrations and 
targeting efficiency required for clinical early arthritis detection. To simulate the light scattering 
in an arthritic hand, we first used CAD software to construct the hand and synovial space around 
the metacarpophalangeal joint (MCP) of the middle finger based on published MR images. The 
fluence rate of emission light was then simulated using a finite element mesh function in 
COMSOL Multiphysics. 
 
5.4 Results 
Near-Infrared Integrin Imaging Agents and their Properties 
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The previous chapter showed that the negative charge on imaging agents can facilitate 
targeting following oral delivery by increasing the target specificity, extending circulation in the 
body long enough to be taken up by antigen positive cells, retaining the agent in cells after 
receptor mediated internalization (due to their residualizing nature), and increasing oral 
absorption. In this study, we employ this method for the detection of RA and study the 
differences between two negatively charged imaging agents – IRDye800CW and AF680 agents – 
for more detailed structure-function relationships. The structure and physicochemical properties 
of the two imaging agents are shown in figure 5.1. The two agents have similar molecular 
weights, formal charge and binding affinities, with the most notable differences being in their 
plasma protein binding (Table 5.1).  
	
Figure 5.1 Imaging agent structures 
	
Table 5.1 Physicochemical properties of both agents 
 IRDye800CW AF680 
Molecular Weight 1393 1249 
Excitation/Emission(nm) 774/789 679/702 
Charge -4 -3 
Affinity ± S.D. (nM) [𝜶v𝜷3] 1.7 ± 0.3 2.7 ± 0.6 
Affinity ± S.D. (nM) [𝜶v𝜷5] 1.5 ± 0.4 2.1 ± 0.4 
Affinity ± S.D. (nM) [𝜶iib𝜷3] Not detectable Not detectable 
Effective Affinity ± S.D. 0.7 ± 0.3 1.1 ± 1.7 
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(nM) [RAW 264.7 cells] 
PPB ± S.D. (%) 91 ± 2 78 ± 3 
% Absorbed - SC* 91 ± 10 100 ± 10 
% Absorbed - PO* 2.3 ± 2.2 1.5 ± 1.3 
 
Near-Infrared Integrin Imaging Agents Target Inflamed Joints after Subcutaneous Injection 
 
To study the effect of the physicochemical properties of the two agents on absorption and 
targeting, they were administered subcutaneously in CAIA mouse models. Both agents are 
rapidly absorbed with high subcutaneous bioavailability (Table 5.1). Images at 48 hours post SC 
injection (Fig. 5.2) showed that the inflamed joints (arrow) had significantly higher signal than 
non-inflamed joints (arrowheads) for the IRDye800CW agent but was similar for the AF680 
agent. Healthy mice were also injected with the same doses of the both agents, and showed 
significantly lower signal for the IRDye800CW agent (p<0.0001) and not significantly different 
signal for the AF680 agent when compared to inflamed joints (Fig. 5.2).  
 
  	
Figure 5.2 RA detection and average signal difference between inflamed and healthy tissue 
post SC delivery at 48 hours. 
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The biodistribution data shows lower uptake of the AF680 probe likely due to the faster 
clearance of the AF680 probe from the body (Fig. 5.3) 163. The above results along with the 
higher oral absorption led to the selection of the IRDye800CW agent for oral delivery. 
	
Figure 5.3 Biodistribution and plasma clearance at 48 hours post SC delivery 
 
Oral Delivery of IRDye800CW Integrin Agent Targets Macrophages in Inflamed Joints 
 
The IRDye800CW agent showed high uptake in inflamed joints when delivered 
subcutaneously and orally. A low affinity stereoisomer of the targeting ligand was conjugated 
with IRDye800CW and dosed orally in mice with inflamed joints. SC delivery gave the highest 
specific signal at 6 hours post administration versus 24 hours for PO delivery. This is likely 
attributed to the kinetics of absorption for the two routes of administration. The time of 
maximum plasma concentration for SC and PO delivery are 1 hour and 2.5 hours275 post 
administration, respectively. The signal in the healthy joints continued to drop with time, which 
increased the contrast between inflamed and healthy paws at 48 hours (Fig. 5.4). The low uptake 
of low affinity agent in the joints of these mice confirmed the targeting specificity of the high 
affinity agent.  
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Figure 5.4 Whole animal fluorescence images and average signal at 6, 24 and 48 hours 		 			
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The biodistribution data was similar for the high affinity agent irrespective of the route of 
delivery and significantly lower for the low affinity binder.   
																														 	
Figure 5.5 Biodistribution data at 48 hours post delivery 
Ex-vivo labeling of histology slides showed macrophage infiltration in the inflamed 
ankles and lack of staining in the healthy ankles (Fig. 5.5). The presence of macrophages 
correlated with significant uptake of the orally delivered IRDye800CW agent in inflamed ankles, 
and low uptake of the low affinity stereoisomer highlighted the specificity of the imaging agent.  
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Figure 5.6 Histology staining of ankle tissue from mice 
 
Computational Modeling Indicates Targeting Efficiencies are Sufficient for Detection at Clinical 
Depths 
A potential limitation of this technique for detecting clinical RA is the depth of imaging 
of NIR fluorescence. To facilitate translation between the animal model results and clinical 
depths, we created a CAD model of a human hand to simulate NIR epifluorescence imaging of 
targeted molecular imaging agents in the synovial tissue at clinically relevant depths (Fig.5.6). 
Based on the thickness of the tissue relative to the scattering length of NIR light, the diffusion 
approximation was used along with a light source located one scattering length within the top 
surface of the hand. The joint location is below this depth based on MRI images. High resolution 
images of the hand joint 276 were used to generate a 3D model of the synovial space where 
molecular imaging agents would bind their target during inflammation. The shape and thickness 
of the synovial space was based on sagittal, coronal and transverse images of the joint.  
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Figure 5.7 Schematics of hand and joint placement used in the COMSOL model 
 (A) CAD file of the hand and synovial space with 0% swelling. (B) A cross-sectional view (at 
the dotted line in A) of the synovial space based on an MRI of the metacarpophalangeal joints 
from Nieuwenhuis et al. 277. (C) A zoomed in representation of the box in B showing the light 
source placed one scattering distance below the skin surface.  (D-F) Model of the synovial 
membrane based on MR images from Theumann et al276. Scale bar = 10 mm.      
 
A two-step simulation in COMSOL was employed where the excitation light was first 
simulated from a planar source shining on top of the hand and used to calculate the imaging 
agent absorption and emission. The excited agent then acted as the source for the emission light 
simulation. The imaging agent concentration in the synovial tissue was varied while the 
concentration in the remainder of the tissue was kept at a constant level to capture background 
autofluorescence and non-specific agent accumulation in healthy tissue. Surface fluence was 
D E F 
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used to determine the image intensity while varying the concentration ratio between the synovial 
tissue and hand. Optical phantoms were used to validate the simulations, and the experimentally 
measured TBR values were similar to those predicted by the simulation. The concentration ratios 
between the synovial space and surrounding tissue (e.g. 10:1) were proportional to the TBR as 
expected (Fig 5.7). The discrepancy between the optical phantom and the simulations likely 
resulted from the increased experimental depth, measured at 3.4 mm for the 5:1 and 2.6 mm for 
the 10:1 phantoms, compared to the depth of 2.3 mm in the simulation.  
 
 
Concentration Ratio COMSOL Predicted TBR 
Optical Phantom 
TBR 
Phantom depth 
(mm) 
10:1 3.1 ± 0.1 3.2 +/- 0.7 2.6 +/- 0.5 
5:1 1.92 ± 0.09 1.7 +/- 0.1 3.4 +/- 0.9 
Figure 5.8 COMSOL model and optical phantom results 
Simulation Optical Phantom 
10:1 
5:1 
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For positive identification of an inflamed joint, the signal must be higher than the 
background variability (the contrast to noise ratio). While the actual values may vary due to the 
reasons listed above, 64% variability in the background intensity was chosen as a reasonable 
estimate of late imaging time background standard deviation and the origin of this value is 
explained further in the discussion section. Since the average signal from the joint would be 
compared to a background signal with a measured standard deviation, assuming a Gaussian 
distribution in the background signal compared to a fixed value of joint signal, the threshold 
CNR for detection is similar to a z statistic. From the cumulative normal distribution table, a 
CNR of 1.65 gives a 95% probability of positive signal relative to the background. Therefore, 
interpolating the CNR values from Table 5.2, probes with 5.5:1 and 6.5:1 concentration ratios 
between synovial tissue and background tissue are necessary for a 95% and 98% probability of 
positive detection of inflammation, respectively. Based on the estimated concentration ratios 
from mice, this level of contrast is achieved with these agents following either oral or SC 
delivery (Fig. 5.8). 
 
Table 5.2 TBR values from COMSOL model for varying concentration ratios 
TBR 10:1 5:1 2:1 1:1 
0% 3.1 ± 0.1 1.92 ± 0.09 1.23 ± 0.06 1.04 ± 0.05 
5% 3.2 ± 0.1 1.98 ± 0.09 1.25 ± 0.06 1.04 ± 0.05 
10% 3.3 ± 0.1 2.01 ± 0.09 1.26 ± 0.06 1.04 ± 0.05 
20% 3.4 ± 0.2 2.09 ± 0.09 1.29 ± 0.06 1.04 ± 0.05 
 
Table 5.3 CNR values from COMSOL model for varying concentration ratios 
CNR 10:1 5:1 2:1 1:1 
0% 3.2 ± 0.2 1.4 ± 0.1 0.36 ± 0.09 0.07 ± 0.07 
5% 3.4 ± 0.2 1.5 ± 0.1 0.38 ± 0.09 0.07 ± 0.07 
10% 3.5 ± 0.2 1.6 ± 0.1 0.41 ± 0.09 0.07 ± 0.07 
20% 3.8 ± 0.2 1.7 ± 0.1 0.44 ± 0.09 0.07 ± 0.07 
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Figure 5.9 Probability of RA detection based on COMSOL results 
Required concentration ratio for positive identification based on the z-statistic and the estimated 
concentration ratio achieved in the mouse model.  
 
5.5 Discussion 
Early detection of RA could enable therapeutic intervention before the disease has caused 
significant irreversible damage, thereby improving patient outcomes. Clinical data suggests that 
it may even be possible to cure the disease if diagnosed early and accurately278. Imaging results 
from ultrasound and MRI are a proven indicator of RA development independent of 
autoantibody status and clinical features. However, both methods have limitations for 
widespread screening. NIR fluorescence molecular imaging has the potential to detect the 
disease in a minimally invasive manner by providing both spatial and molecular information 
within the joints. This imaging modality would have several advantages over ultrasound by 
simultaneously capturing data from multiple joints using FDA approved NIR hand scanners and 
yielding quantitative molecular information from targeted probes. The cost of imaging and time 
for acquisition is also much less than MRI, and it has safety benefits from the use of non-ionizing 
radiation relative to PET and SPECT molecular imaging modalities. Current clinical efforts have 
focused on non-targeted ICG given its FDA approval for imaging in the clinic. However, the low 
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contrast provided by this non-specific protein-binding dye requires dynamic imaging 279 to parse 
increased uptake in the joints from normal background and surface vessel fluorescence. Targeted 
imaging could provide significantly higher contrast ratios for more definitive image analysis, 
diagnosis, and follow up testing. Therefore, researchers are exploring a variety of imaging agents 
including 99mTc-MDP 280, PSVue 794 281, αCD11b-APC combined with MMP750 282, NIR2-
folate 283, MMP-3 specific polymeric probe using NIRF 284, protease activated NIRF probes 
(sensitive to Cathepsin B) 268, integrins 285,286 and AP39-TSC 287. The research into new imaging 
agents continues in order to develop probes capable of detecting this early stage of the disease. 
However, many of these methods include intravenous delivery and/or radiolabels, and the 
required imaging agent uptake ratios and molecular targets have not been analyzed in a 
quantitative fashion over clinically relevant length scales. In this work, we used an integrin 
binding ligand conjugated with a NIR fluorophore and tested its ability to detect RA in a CAIA 
mouse model using SC and oral delivery. We also simulated NIR fluorescence imaging of 
targeted synovial tissue in a human hand while varying the target to background ratios using 
COMSOL Multiphysics to determine the translatability of this technique to humans. 
Due to their efficient targeting and optical properties, the IRDye800CW and AF680 
agents were delivered by SC and oral administration in a mouse CAIA model of RA. Our 
previous work showed high affinity for αvβ3 in transfected HEK-293 cells (Chapter 3). In the 
current study, we tested the affinity in a plate assay to 3 different heterodimers, αvβ3, αiibβ3 and 
αvβ5, and in mouse macrophage cells (RAW 264.7 cells). Interestingly, the affinity of the AF680 
probe was much higher for αvβ3 in the context of cells. However, the slightly better affinity as 
measured using the plate assay and mouse macrophage cells is more consistent with the low 
uptake in vivo. Although the targeting ligand has high specificity for αvβ3 over αvβ5 97, the 
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modification with these two dyes increases the cross-reactivity with αvβ5, which is also 
upregulated on macrophages 82. However, no binding to αiibβ3 was detected (Table 5.1), which is 
important to avoid any safety issues with binding to this heterodimer on platelets288.	Both the 
agents are structurally very similar, with the AF680 agents having the benefit of faster clearance 
from the body, which reduces background signals. However, the IRDye800CW agent performed 
significantly better than the AF680 during in vivo experiments. The rapid clearance of the AF680 
agent is not beneficial when there is a significant absorption phase, such as SC or oral delivery, 
in contrast to IV delivery. Rapid clearance during the absorption phase results in lower 
maximum concentrations within the body. Another reason is that the autofluorescence in the 680 
channel is higher than the 800nm channel, compounding the issue of low concentrations in the 
blood.  
The IRDye800CW agent showed specific targeting and high target to background ratios 
in the CAIA mouse model when delivered subcutaneously, and given the similar kinetics 
following oral delivery, we hypothesized it would provide specific targeting following oral 
administration. Fig. 5.4 confirmed this hypothesis with the major difference between the two 
methods of administration being the higher variability in target tissue and background following 
oral delivery. The low-affinity stereoisomer of the IRDye agent had lower uptake following oral 
adminsitraiton than the healthy mice, indicating some binding to integrins in the healthy tissue. 
Microscopically, significant uptake is seen in macrophages in and around the synovium in 
inflamed joints (Fig. 5.6). Both delivery methods produce signals higher than seen in healthy 
joints, especially at later times. The subcutaneous route results in less variability in absorption; 
however, both the signal and background intensities are proportional to the absorbed dose, so the 
TBR is similar between both routes.  
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Based on the TBR achieved in the animal experiments, we next used computational 
modeling to scale the results to clinical depths. This was achieved by building an optical imaging 
COMSOL model to simulate various target to background concentration ratios and different 
extents of joint swelling (Fig. 5.7). The results showed that the TBR and CNR values are 
strongly affected by the target to background concentration ratio and only weakly impacted by 
the extent of joint swelling i.e. thickness of the synovium. The regions of interest used to 
calculate the TBR and CNR avoided the diffuse light at the edges of the joint. The optical 
phantom experiments were conducted to validate the in silico results, and these data were largely 
in agreement. The standard deviation for the experimental data was large owing mainly to the 
experimental error in placing the joint at a certain depth below the surface of the hand. The 
simulations had the joint at 2.33 mm from the surface, whereas experimentally that distance 
ranged from 2.5 to 4 mm.    
Based on the COMSOL simulations, these results can be used to aid in NIR fluorescence 
molecular imaging agent design for RA. First, a minimum concentration ratio must be achieved 
for signal detection above background fluctuations. Random fluctuations of the background 
signal introduce noise to the image, impairing the image detectability. As it is important to 
distinguish true joint inflammation from signal fluctuations in normal tissue for accurate 
diagnosis, the detectability should be high, which is best described by the CNR 289. The 
variability in background signal is a complex function of the imaging probe properties, 
background tissue physiology, imaging time versus pharmacokinetics, characteristics of the 
imaging system, and optical properties of the probe and tissue. In general, early imaging times 
after imaging agent delivery have the potential for increased heterogeneity in the background due 
to large gradients between the blood and tissue, while at longer times these gradients have 
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dissipated. Likewise, the background signal in the NIR region is often dominated by non-specific 
probe signal rather than autofluorescence, lowering the impact of optical properties and 
instrumentation (where spectral deconvolution, for example, would not improve the contrast for 
probe-dominated background signal). To obtain a reasonable estimate for this variability, 
reported mouse and clinical data were used to estimate the background standard deviation. These 
data were taken at long times after administration (24 hrs post-injection) to minimize variability 
due to transient redistribution from the blood. Assuming that the variability correlates with the 
background signal (i.e. a higher absolute background signal results in higher absolute variability 
such that the standard deviation is proportional to the signal), a previous report in mice indicated 
a background variability of 64% for antibodies 72 hr after delivery 274. A clinical imaging sample 
indicated a background variability (after subtracting non-tissue signal from the in vivo 
background signal and error propagation) of 51% at 24 hrs post-injection of the small molecule 
ICG 290. While the actual values may vary due to the reasons listed above, 64% variability in the 
background intensity was chosen as a reasonable estimate of late imaging time background 
standard deviation. 
To estimate the required CNR values for clinical detection, we examined the probability 
of positive identification of an inflamed joint. According to the Rose Criterion, the CNR of an 
object must exceed 3 to 5 in order to be considered detectable 291. It is also possible to identify 
signal with a CNR less than 3, but it suffers from a higher probability of misidentification. For 
example, an image with CNR of 2 has a probability to misidentify signals from one tissue to 
another of 16% 292. However, the Rose Criterion applies to situations where the location of the 
target is unknown, such as identification of a breast tumor293. When imaging the hand, the 
intensity of signal from the joints is compared to the background (non-joint) tissue, both with 
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anatomically defined locations. Since the average signal from the joint would be compared to a 
background signal with a measured standard deviation, assuming a Gaussian distribution in the 
background signal compared to a fixed value of joint signal, the threshold CNR for detection is 
similar to a z statistic. From the cumulative normal distribution table, a CNR of 1.65 gives a 95% 
probability of positive signal relative to the background. This corresponds to a target to 
background concentration ratio of ~5.5:1 and a concentration ratio of ~6.5-1 is required for a 
98% probability in detection. 
	
Figure 5.10 Concentration ratio scale up 
Schematic of inflamed paw with epifluorescence imaging (excitation and emission occurring 
from the top). A healthy paw would have an identical schematic without the inflamed tissue.  	
Average healthy paws: 2.6mm 
Average extent of inflammation: 0.4mm 
Imaging intensity ratio between inflamed paws and healthy paws (TBR) = 4 
 
Two approaches were used to scale the imaging signal intensity to the concentration ratio 
between inflamed and healthy paws: a simple linear scaling shown below and a diffuse light 
approximation of fluorescence intensity294. Both results gave similar answers, which was 
anticipated given the small thickness of the mouse paw relative to NIR light penetration. For the 
linear scaling, let the concentration in the inflamed tissue be X nM and in the healthy tissue be Y 
nM.  
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𝑇𝐵𝑅 =  𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝐼𝑛𝑓𝑙𝑎𝑚𝑒𝑑 𝑃𝑎𝑤𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖 𝑛 𝑖𝑛 𝐻𝑒𝑎𝑙𝑡ℎ𝑦 𝑃𝑎𝑤  
𝑇𝐵𝑅 =  0.5 𝑌 + 0.4 𝑋 + 2.1 (𝑌)2.6 (𝑌) = 4 
Solving the equation, we get  
The concentration ratio of inflamed to healthy tissue is 19.5. By scaling the 
concentrations from the CAIA mouse model (Fig. 5.10), we demonstrate that this ratio is ~4 
times larger than the theoretical requirement and should be sufficient for detection at clinical 
depths. 
Simulations can also guide target selection. If the background signal from 
autofluorescence and non-cleared probe is on the order of 3-5 nM (which is highly dependent on 
the instrument but estimated based on the IVIS imaging system), a 10:1 ratio would require ~30 
to 50 nM of probe in the target tissue. Assuming 5x108 cells/mL, this requires ~40,000 to 60,000 
receptors per cell if the target is universally expressed. If only 25% of the cells in the synovium 
express the target, these requirements reach ~200,000 receptors/cell. This is assuming an agent 
based on binding rather than amplification from enzyme activation. Few targets have this high 
level of expression, but the αVβ3 integrin and folate receptor are two promising candidates (Table 
5.4). The αVβ3 expresses ~1.7x105 receptors per activated endothelial cell 224, 2x105 receptors per 
macrophage 225, and 106 receptors per osteoclast 295. It also has a clinical precedent with 
radiolabeled molecules 286. Similarly, the folate receptor is expressed at 3.2x105 receptors per 
macrophage 296 and has a clinical precedent 297. Notably, radiolabeled agents achieved a 90 nM 
concentration within the joints 298. Ultimately, these values may need to be updated when new 
experimental measurements are available, but they provide a benchmark for comparison during 
probe development. 
X
Y =19.5
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Table 5.4 Potential targets for RA detection 
Target Expression Drug Size Affinity Reference 
Integrin 𝛼v𝛽3 
1.7x105 
(endothelial 
cells) 
2x105 
(macrophages) 
1x106 
(osteoclasts) 
 
Integrisense 
750 1278 Da 4.2 nM Kossodo 2010 
IRDye 
800CW Agent 1397 Da 4.8 nM Experimental 
AF680 Agent 1252 Da 0.3 nM Experimental 
Antibodies ~150 kDa 0.1 nM Barbas 1993 
Folate 
Receptor 
3.2x105 
(activated 
macrophages) 
Folic acid 441.4 Da 0.1 nM Sudimack 2000 
 99mTc-EC20 745.2 Da 3 nM Leamon 2002 
 EC0565 2740 Da 0.028 nM* Lu 2015 
 BGC 945 647.6 Da ~0.35 nM* Gibbs 2005 
RANK - RANKL ~35 kDa 0.109 nM Zhang 2009 
MMP 
- Sulfonamide Inhibitors ~400 Da 
0.3 nM 
(MMP-13) Lovejoy 1999 
 Batimastat 478 Da 3 nM (MMP-1) Botos 1996 
 Marimastat 331 Da 
5 nm (MMP-
1) 
 
Michaelides 
1999 
 Prinomastat 420 Da 17 nM (MMP-1) 
Humphrey 
2003 
Adhesion 
Molecules 
- Rituximab ~145 kDa Kd = 4.5 nM Mössner 2010 
 Ocaratuzumab ~145 kDa Kd = 100 pM  
 Catumaxomab ~150 kDa Kd = 0.56 nM Ruf 2007 
Chemokine 
Receptor 
- CXCL10 (IP-10) 8.8 kDa Kd = 69 pM Qin 1998 
 CXCL9 (MIG) 11.7 kDa Kd = 90 pM  
 MIP-1𝛃 (CCL4) 7.8 kDa IC50 = 0.41 nM Laurence 2001 
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Model Limitations 
 
The order-of-magnitude values for fluorescence intensity and concentration ratios needed 
for clinical detection can provide guidance on the types of probes that should be developed. 
However, there are several limitations to the model. First, the 3D synovial space and hand are 
only approximations of the complex tissue structures present within the hand, which may impact 
light propagation. When drawing the joint in Solidworks, the exact 2D sketches of the joint were 
extracted from the three anatomical planes of its MR images (sagittal, coronal and transverse 
view). Then the 3D model was constructed by the lofting feature in Solidworks, using the three 
sketches of top, middle and bottom planes of the transverse view as bases, and sketches on 
sagittal and coronal planes as guidelines. Thus, although the model has the same anatomical 
cross-section views as the MR images, the overall 3D shape is an approximation based on the 
available MR images. Second, the optical phantom is also an experimental approximation of the 
behavior of light in living tissue. There are no internal boundaries in the optical phantom, and the 
absorption and scattering are homogeneous average values for tissue. Third, the variability in 
background signal intensity was estimated based on animal data and limited clinical data with 
ICG and could vary from the estimated value.  
 
 
5.6 Conclusion 
 In conclusion, self-administered NIR fluorescence molecular imaging has strong potential 
to serve as an early detection method for rheumatoid arthritis due to its low cost, ease of use, and 
target specificity. The proper design of molecular imaging agents can ensure sufficient specific 
targeting to achieve the necessary sensitivity for accurate clinical screening and early therapeutic 
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intervention. The current COMSOL model results indicate sufficient signal at clinical depths for 
early detection of RA. 	
5.7 Experimental Methods 
In Vivo Experiments 
To determine the absorption following SC administration, 1.5 nmoles of the imaging 
agent (~0.1 mg/kg) were administered in separate 8-10 week old female black-6 mice via SC and 
intravenous (IV) injection (Fig. S2). Retro-orbital blood draws were conducted at 5, 15, 30, 60 
120, 240, 360 and 1440 minutes post-administration for SC delivery and at 1, 3, 5, 15, 30, 60, 
180, 360 and 1440 minutes post-administration for IV delivery. 10ul of blood was mixed with 
20ul PBS-EDTA and spun down at 2000g for 1 minute. The plasma (supernatant) was then 
pipetted into a 384 well plate and the fluorescence of the sample was measured on the Odyssey 
CLx. The signal was converted into a plasma concentration of the imaging agent using a 
calibration curve in mouse plasma. Area under curves (AUC) for the mice were calculated using 
the trapezoidal rule and % absorbed was determined by the ratio of the AUC of SC to IV. For 
oral delivery, the percent absorbed was measured as previously reported in Bhatnagar et al299. 
The collagen antibody induced arthritis (CAIA) model was used for imaging (Chondrex; 
Redmond, WA).  Female Balb/c mice of 8-10 weeks of age were used for this study. 1.5 mg of 
the antibody cocktail was administered by intraperitoneal (IP) injection into the mice (Jackson 
Laboratories; Bar Harbor, ME). 3 days later 50 ug of LPS was administered via IP injection. The 
extent of paw and ankle inflammation was measured using calipers, and once inflammation was 
seen (8-10 days after the antibody injection), the mice were administered doses of the imaging 
agents.  
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Imaging agents were administered by either SC injection (dorsal side between the 
shoulder blades) or oral to the CAIA model mice with inflamed joints or control mice with no 
inflammation. For SC, the mice were anesthetized using 2.5% isoflurane and the imaging agents 
were either co-administered at a dose of 1.5 nmole each in the same mouse or dosed individually 
at 1.5 nmole. For oral delivery, a 24-gauge needle (Fine Science Tools; Forster City, CA) was 
used to administer a 75 nmole dose. Post injection, the mice were imaged on an IVIS Spectrum 
(Perkin Elmer; Waltham, MA ) at 6, 24 and 48 hours. After the 48-hour image the mice were 
euthanized and all their organs were resected for biodistribution. The ankle was snap frozen in 
OCT using isopentane cooled on dry ice for histology. The biodistribution protocol is previously 
reported (Chapter 4.7), but briefly the organs were minced with a razor blade, weighed, and 
digested in Eppendorf tubes using a collagenase (Worthington Biochemical; Lakewood, NJ; Cat. 
No. CLS-4) solution (5 mg/ ml) in RIPA buffer (Boston BioProducts; Ashland, MA) at 37°C for 
20 minutes. The organs were sonicated, digested for 20 minutes at 37°C using a 50:50 trypsin 
and RIPA buffer solution and sonicated. A dilution series of the resulting mixture was scanned in 
a black walled 96-well plate using an Odyssey CLx. Absolute quantification was obtained by 
comparison with a calibration curve. The uptake values were normalized to the average amount 
of probe that reached the systemic circulation (absorbed dose) per gram of tissue. 
Histology 
The frozen ankle was sectioned into 10µm slices on a cryostat using a tungsten carbide 
blade. The tissue was not fixed to avoid loss of fluorescence signal. The slice was stained ex-
vivo with an anti-Mac3 antibody (BD Biosciences; San Jose, CA) labeled with Alexa Fluor 555. 
The slides were then washed with PBS and imaged on an Olympus FV1200 confocal microscope 
with a 543 and 750 nm laser line.  
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Governing Equations for COMSOL Model 
This model uses a steady state diffusion equation to approximate the propagation of light 
in highly scattering media based on the thickness of the human hand and high albedo of NIR 
light 274,276,277:   
 
where u is the fluence rate of light, D is the diffusion coefficient, 𝜇! is the absorption coefficient, 
and f  is the light source. Parameters used for the simulation are listed in Table S1 and S2. Both 
light properties of 800 nm and 680 nm dyes are considered. The problem is divided into two 
simulation steps: excitation followed by emission. For the excitation light: 
 
The planar light source is positioned at one scattering distance below the top surface of 
the hand, where the scattering of the light is assumed to be isotropic (e.g. 274,300,301). Fluorophores 
in the hand are excited by light based on their absorption coefficient and the photon density of 
the excitation light. They emit fluorescence signals based on their quantum yield, which 
propagates through the tissue and can be detected at the surface of the hand. Autofluorescence in 
the hand is also included in the model as an ‘equivalent dye’ concentration in the tissue.  For the 
emission light: 
 
Both the excitation and emission light simulations use Robin boundary conditions at the 
outer surface of the hand.  
   
 
 
𝛻 ∙ −𝐷𝛻𝑢 + 𝜇𝑎𝑢 = 𝑓	
𝛻 ∙ −𝐷𝛻𝑢 + 𝜇𝑎 𝑢 = 0 	
𝛻 ∙ −𝐷𝛻𝑢 + 𝜇𝑎𝑢 = 𝜂 ∙ 𝜇𝑓𝑥 ∙ 𝑢 ∙ [𝐶]𝑗𝑜𝑖𝑛𝑡 	
−𝒏 ∙ −𝐷𝛻𝑢 −  𝑢 /(2 ∙ 𝐶𝑟)  = 0	
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CAD Drawing of Hand MCP Joint Using SolidWorks 
To obtain results at clinical relevant depths, a CAD hand file (GrabCAD; Cambridge, 
MA) was used and scaled to the size of a human hand. The planar light surface was created by 
duplicating the top surface of the hand using SolidWorks (SolidWorks; Concord, MA) and 
translating that surface one scattering distance beneath the top of the hand (Fig. 5.7).  Next, the 
synovial space around the MCP joint in the middle finger of the hand was made using 
SolidWorks. The size and shape of the membrane (Fig. 5.7 D-F) was based on sagittal, coronal 
and transverse MR images of the MCP joint276. The size of the base case synovial membrane is 
referenced from the scale bar on the coronal and transverse views of the MR images. The 
membrane position in the hand is determined from the MR image. 
 
Development of COMSOL Model 
The Helmholtz equation in COMSOL Multiphysics (COMSOL Inc.; Burlington, MA) 
was used for simulating the light diffusion equation at steady state. The constructed CAD model 
was imported into COMSOL, and the parameters and boundary conditions of the diffusion 
equation were correspondingly assigned. The simulation involves two Helmholtz equations 
depicting the excitation and emission light separately. The finest tetrahedral mesh was used, and 
COMSOL solved the differential equations at a tolerance of 10-5 for four iterations. The 
simulated results were saved as images under volume mode for image post-processing.    
 
Imaging Optical Phantoms 
 An optical phantom was used to validate the COMSOL predictions (Fig. 5.8). The same 
CAD file used for the COMSOL simulations was also used to make a replica of the synovial 
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space using 3D printing (Cube 2, Cubify). A silicone mold of a hand and the 3D printed synovial 
space was used to generate optical phantoms (Fig. 5.11), which consisted of 3% agarose gel (for 
structure), 1% Intralipid (Baxter, Deerfield, IL) and 50 ppm India ink to mimic the absorption 
and scattering properties of human tissue274. IRDye 800CW carboxylic acid (LI-COR 
Biosciences; Lincoln, NE) was added at a concentration of 10 nM to the hand to represent 
background signal and 50 nM or 100 nM to the synovial space to represent specific uptake. The 
synovial space was placed ~2.5 mm from the surface of the hand. Once the gel solidified, it was 
imaged on an IVIS Spectrum (Perkin Elmer; Waltham, MA) and the TBR was calculated using 
the LivingImage software (Perkin Elmer; Waltham, MA).    			 																
Figure 5.11 Optical Phantoms 
(A) A silicone mold of a human hand was used to generate the optical phantom. (B) The CAD 
model of the synovium was used to 3D print a cast (blue) to generate a mold (purple) for the 
joint. (C) Cross-section of optical phantom, with the darker region being the joint. The grey 
region had either 100 or 50 nM of the dye and the healthy tissue in white had 10 nM of the dye. 
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Chapter 6: Conclusion 
6.1 Summary 
In this dissertation, we demonstrated that near infrared molecular imaging agents could 
be orally delivered to detect diseases like breast cancer and rheumatoid arthritis in mouse 
models. Chapter 2 dealt with the validation of a theoretical model that could predict delivery of 
drugs and imaging agents to tumors. The key challenges here were to make sure that the 
computational model was a accurate enough to be able to predict the distribution of drugs to 
tumors based on their physicochemical properties in spite of the heterogeneity in the tumor 
microenvironment. The previously published computational model showed that drugs could be 
categorized into four different classes based on their rate-limiting step of delivery20. The four 
classes are (I) blood flow limited, (II) extravasation limited, (III) diffusion limited and (IV) local 
binding/ metabolism limited agents. One drug or imaging agent was selected for each class based 
on computational predictions and non-overlapping fluorescence spectra. These agents were co-
injected in the same mice to avoid tumor-to-tumor variability. The results showed that the 
computational model accurately described the delivery and distribution of these agents ranging 
from small molecules to antibodies in the tumor. This is of extreme importance as it exhibited 
that we could predict the delivery of these agents to tumors with knowledge of their 
physicochemical properties, which can be obtained from in vitro studies. Drug selection in the 
industry requires rigorous animal testing to prove that the agents work in vivo. This 
computational model can help reduce the amount of time, resources and animals required during 
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initial drug or imaging agent selection by eliminating these agents early on in their development 
if the model shows poor distribution. The model was used to guide our decision-making as we 
went about selecting the ideal imaging agent.  
 In order to find a molecular imaging agent that could be orally delivered we had to decide 
on the target and the ligand to be used. We selected integrin of the form αvβ3 because it is an 
extracellular target, has high expression on breast cancer cells and macrophages, internalizes at a 
relatively fast rate and has well-studied ligands against it. This dissertation was primarily a 
proof-of-concept study to show that detection of diseases was viable post oral administration, 
which led us to pick a target that had several studied ligands against it. This allowed us to 
circumvent the molecular screening step and select a ligand with optimal properties from the 
several published binders against αvβ3. Out of all the published ligands we selected a 
peptidomimetic (structure in Chapter 3.4) that has low molecular weight, high stability, low 
toxicity and high affinity to αvβ3. The ligand had been shown to retain its affinity to αvβ3 after 
conjugation to a NIR fluorophore97. Chapter 3 showed the synthesis of five different 
fluorophores to the ligand and their measured physicochemical properties. The five imaging 
agents were evaluated on three criteria: specific targeting, high oral absorption and good in vivo 
optical properties. Based on these criteria, the IRDye800CW agent, with an oral absorption of 
2.3%, was selected for testing in in vivo for breast cancer detection. While the oral absorption is 
lower than typical small molecule therapeutics, it is relatively good compared to some other 
large hydrophilic molecules (Chapter 3.4) and fulfills the criteria needed for high contrast. The 
rule of thumb for oral absorption of therapeutics is about 30% since they need to saturate their 
target. Imaging agents, on the other hand, only need to be able to differentiate their target from 
background. As the percent oral absorbed increases, so does the signal from the target and 
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background thereby keeping the contrast the same. Therefore, imaging agents are less sensitive 
to the absolute amount absorbed. There is however a lower threshold below which the imaging 
agent is not efficient enough to target the diseased site, estimated to be about 1% in the mouse 
models, which the IRDye800CW agent is well above. It also needs to be highlighted that the oral 
absorption of these imaging agents was ascertained by measuring the amount of agent excreted 
in urine. Therefore, the oral absorption numbers are a conservative estimate of the total amount 
of agent orally absorbed.  
  The IRDye800CW agent was administered at a 5mg/kg dose to nude mice with tumor 
xenografts in their mammary fat pads. Live animal imaging at 6, 24 and 48 hours post 
administration showed that the amount of imaging agent in the tumors remained fairly constant 
over two days; however, the target to background ratio (TBR) increased with time to give a TBR 
of ~4 at 48 hours. The residualizing nature of the imaging agent causes it to remain trapped in 
the tumor while the imaging agent in the background, i.e. healthy tissue, is cleared from the 
body, giving higher TBR values. This was a validation of the initial hypothesis of this 
dissertation as it showed the detection of breast cancer after oral administration of an imaging 
agent that binds primarily to activated macrophages and to a lesser extent breast cancer cells and 
neovasculature. One of the biggest advantages of this technique over current techniques is that it 
has the ability to provide molecular information about the disease. In order to confirm that the 
imaging agent was being taken up specifically in the tumor to provide accurate molecular 
information, we used the stereoisomer of the ligand to synthesize a low affinity stereoisomer 
agent. It has an order of magnitude lower affinity to αvβ3. We dosed mice with 5 mg/kg of this 
control agent and saw significantly lower uptake in the tumors compared to the IRDye800CW 
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agent. This showed that the IRDye800CW agent was being taken up specifically in the tumor 
due to its interaction with the αvβ3  receptor.  
 With the positive identification of breast cancer in mice, we wanted to see if the same 
imaging agent would work in the detection of rheumatoid arthritis (RA) as well. Since the there 
is still a lot to be learned about transient kinetics of imaging agents in the RA microenvironment, 
we decided to subcutaneously (SC) deliver the imaging agent to make sure that we would be able 
to target the macrophages at the site of the disease. SC delivery has similar kinetics to oral 
delivery with a prolonged absorption phase followed by a clearance phase, but it does not have 
the animal-to-animal variability of oral delivery. We also tested another imaging agent in 
conjunction with the IRDy800CW agent, the AF680 agent. It has similar properties to the 
IRDye800CW agent, and since its excitation and emission maxima are very different from that 
of the IRDye800CW agent, we could co-administer both imaging agents in the same animal. We 
used a collagen antibody induced arthritis (CAIA) model in Balb/cJ mice and used a 0.1 mg/kg 
dose for SC delivery. The IRDye800CW agent was significantly better at identifying inflamed 
joints from healthy joints, with the AF680 agent not being able to differentiate between the two. 
The AF680 agent has lower plasma protein binding leading to faster clearance from the body and 
an area under the curve that is 4 fold lower than that of the IRDye800CW agent. The higher 
exposure of the IRDye800CW agent to the target is the reason for the IRDye800CW 
outperforming the AF680 agent. The IRDye800CW agent was then tested in the same CAIA 
mouse model via oral administration and the results showed statistically significant higher uptake 
in the inflamed joints compared to the healthy ones. We also used the low affinity stereoisomer 
control to demonstrate the specific uptake of the IRDye800CW agent in macrophages.  
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 The biggest downside to using fluorescence as an imaging modality is its low depth of 
imaging. In order to test the feasibility of using epifluorescence to detect RA at clinically 
relevant depths in humans, we developed a 3D COMSOL model to run optical simulations and 
mimic the clinical setting. A CAD file of a human hand was built using measurements from 
published MRI scans and simulations were run testing different target to background 
concentration ratios. The target to background concentration ratios are the ratio of the amount of 
imaging agent delivered to the target, i.e. the inflamed joint, to the amount of imaging agent in 
background, i.e. rest of the hand. So, if the target to background concentration is 5, it means that 
the inflamed joint has a five times higher concentration of imaging agent than the rest of the 
hand. The model and its assumptions were validated using optical phantoms with the same target 
to background concentration ratios (Chapter 5.5). The simulations showed that with a target to 
background concentration ratio of 5.5 and 6.5, we have a 95% and 98% chance of detecting the 
inflamed joint. For reference, the in vivo data in mice showed a ~20 target to background 
concentration ratio giving us 3-4 fold buffer when translating this technique to humans.  
 In conclusion, we were able to show sufficient absorption and specific targeting 
of the IRDye800CW in the detection of breast cancer and RA. To implement this technique in 
the clinic, patients would self-administer these imaging agents approximately two days before 
imaging. When they are in the clinic, they can immediately be screened for these diseases. This 
method prevents the need for multiple visits: once to get intravenously injected with the imaging 
agent by a trained professional and then later to get imaged.  	
6.2 Future Work 
This proof-of-concept study showed that molecular imaging agents can be orally 
administered and can identify the site of disease in mice. The development of this imaging agent 
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can be used as a model system to develop other agents that can bind to targets overexpressed in 
other diseases, thereby broadening the range of diseases that can be detected through annual 
screenings. Lowering the variability in the absorption of the imaging agent by using permeability 
enhancers can make the technique more robust.  
 
Development of imaging agents 
Since integrin αvβ3 is highly expressed on macrophages that are present at sites of 
inflammation, this imaging agent alone runs the risks of identifying sites of inflammation as 
breast cancer itself. The best way to reduce these false positives would be to co-administer 
another molecular imaging agent that binds a different biomarker and provides more molecular 
information about the disease. The integrin agent would then provide high sensitivity while the 
second agent would improve the specificity. Future work will involve identifying potential 
targets for co-administration of the imaging agents and ideal ligands to bind to these targets. The 
imaging agents will have excitation and emission spectra in the 600-700 nm range to avoid 
overlap with the IRDye800CW agent. Initial theoretical research suggests that calcium-chelating 
agents would be ideal as a second imaging agent. Literature shows the presence of calcium 
deposits in certain breast cancers302, which would mean that high signal from both the imaging 
agents would indicate the presence of a tumor rather than being a false positive. Other potential 
targets for breast cancer are prostate specific membrane antigen (PSMA) and matrix 
metalloproteinases (MMPs), both of which are upregulated in breast cancers, have low or no 
expression in healthy tissue, and are extracellular targets303,304. In the case of RA, the calcium 
chelating agents would bind to bone and the integrin binding agents would bind to macrophages. 
The ratio between two agents would potentially help us differentiate between RA and ankylosing 
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spondylitis. Higher signal from the calcium-chelating agent would suggest ankylosing 
spondylitis, whereas higher signal from the integrin binder would suggest RA. This would help 
avoid misidentifying the disease in RA since both of diseases have inflammation around the 
joints as a symptom.  
Reducing variability in oral absorption 
One potential issue with this technique is the high variability in the administered oral 
dose. Below a certain threshold of absorption, the signal from the site of disease is not sufficient 
to provide high contrast to noise  due to low uptake from the circulation. One method of reducing 
this variability and potentially increasing the absorbed fraction is the use of permeability 
enhancers like in the case of semaglutide305, which is in phase 3 clinical trials. Permeability 
enhancers like fatty acids could help increase the amount of dose absorbed thereby providing 
more robust signal using this technique.   
Our hypothesis for absorption of these large hydrophilic molecules is the amphiphilic 
structure of the imaging agents, with a lipophilic ligand conjugated to a hydrophilic fluorophore. 
We hypothesized that if we could make the ligand portion of the imaging agent more lipophilic 
we could potentially get higher absorption. Fig. 6.1 shows the structures of the imaging agent 
used in this dissertation and the more lipophilic version of it with the carboxylic acid replaced 
with an ester. Preliminary studies show that the absorption using the prodrug version of is more 
consistent and is higher than the carboxylic acid version (Fig. 6.1). Next steps will include 
studying the affinity of the prodrug imaging agent to αvβ3, its cleavage by carboxylesterases in 
blood and identifying what fraction of the dose is cleaved when collected in urine.  
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Figure 6.1 Structure and oral absorption of the IRDye800CW agent and its prodrug 
version 
Early detection in RA 
For the purposes of these proof-of-concept studies we had diseases in their peak states. 
The eventual goal is to be able to detect the disease early on. In order to identify how early on 
after the onset of the disease we can identify it, future work will involve inducing RA in rats and 
orally dosing the imaging agents at varying times post induction to identify the time at which we 
can confidently diagnose the disease.  
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Treatment monitoring  
Another application of orally delivered imaging agents, other than early detection, is 
treatment monitoring. The current standard of treatment is weekly doses of methotrexate and 
treatment monitoring follow ups are subjective and conducted after several weeks to months. It 
would be ideal to have a quantitative method to measure the response at the diseased site days 
after treatment to offer the doctor with more information about whether the dose needs to be 
increased or if they need to switch to a biologic dose. The technique proposed in this dissertation 
would be ideal to monitor to the treatment of the disease. After starting treatment the patient 
could take a pill of the imaging agent every 2-3 weeks and could be imaged by their doctor to 
ascertain whether there needs to be any change in the course of action or if the disease is being 
treated adequately. Since this technique provides quantitative data, doctors can follow the data 
over time to make more informed decisions regarding the health of their patients. Future work to 
show the benefits of this method, rats will be induced with RA, treated with methotrexate and 
will be dosed with the imaging agent and imaged periodically to follow the progression of the 
disease.  
In summary, we will work on developing orally available imaging agents for different 
targets to co-administer two imaging agents and provide extensive molecular information about 
the disease. Permeability enhancers or the prodrug approach will be studied to provide consistent 
and sufficient delivery of imaging agents post oral delivery.  The imaging agents will be used in 
rat models to study how early RA is detectable and to provide quantitative data for treatment 
monitoring to indicate any required increases in dosage or frequency of doses.  
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6.3 Challenges and Future Directions 	
Fluorescent imaging agents have enormous potential in modern medicine. The last 
decade has seen several studies conducted on the use of specific and non-specific fluorescent 
agents for guided surgeries. Their ability to provide high spatial resolution in surgeries is highly 
beneficial to patient outcomes, as is the low risk (non-ionizing radiation) of the imaging 
modality. Another avenue being actively studied is the use of biologics as imaging agents, where 
highly specific antibodies can easily be tagged with NIR fluorophores. These can be used either 
in surgeries as their high specificity can clearly help delineate healthy and diseased tissue or can 
be self-administered for disease detection (e.g. research in oral cancer detection). The versatility 
of these imaging agents lies in the fact that these fluorophores can be easily conjugated with 
ligands (small molecules or biologics) and are stable over long periods of time compared to 
radiotracers with half-lives ranging from hours to days. They have fundamental advantages over 
related techniques, such as providing molecular information (compared to anatomical imaging), 
the spatial location of these biomarkers (compared to blood tests), and are less expensive with 
lower risks from non-ionizing radiation (compared to PET or SPECT modalities). However, 
there are limitations and challenges that lie ahead before routine implementation in the clinic. 
Specifically for the proposed method presented in this thesis, future challenges include 
the sensitivity and specificity of the method in breast cancer and rheumatoid arthritis, the oral 
absorption in humans versus rodents and associated variability, and the logistics surrounding the 
implementation of a new imaging modalities. Each one of these aspects is presented below along 
with some potential avenues forward to overcome these challenges. 
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Sensitivity and Specificity for Screening 
With respect to the sensitivity and specificity for breast cancer detection, the primary 
concern for sensitivity is the spatial resolution of lesions embedded deep in breast tissue. This is 
because the biomarker is found on tumor associated macrophages, neovasculature, and most 
breast cancer cells, therefore, the expression should occur in most/all tumors. Studies using 
diffuse optical tomography and non-specific agents have demonstrated the ability to detect 
tumors of ~1cm (and ~8mm in diameter for phantoms with similar contrast ratios). The 
expectation is that using molecular imaging agents for this purpose could help detect lesions 
smaller than 1cm in size due to the high specificity of the agents. Tumors smaller than this would 
require an alternative technique, but it is still unclear whether these smaller tumors are important 
for detection. Some evidence indicates that the tumors detected at a small size may typically be 
slower growing tumors that may not require treatment. Future studies from mammography 
results should help shed light on these issues. If these small lesions are important to reduce 
mortality, there is also ongoing research in techniques like high dynamic range fluorescence 
laminar optical tomography and optoacoustic imaging that can help increase the spatial 
resolution and depth of imaging of this technique, respectively.  
For specificity, a major challenge is differentiating benign versus malignant tumors. 
Although αvβ3 expression is higher on more aggressive tumor types, it is also expressed in some 
benign lesions such as fibroadenomas. One benefit of fluorescence imaging agents is the ability 
to co-administer a pair of imaging agents that have little to no overlap in their excitation-
emission spectra. This allows for multi-channel imaging to screen multiple biomarkers of the 
same disease to help differentiate malignant vs. benign disease. If the specificity from multiple 
biomarkers is not sufficient, then this method may be primarily suited for women with dense 
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breast tissue, since the NIR approach would allow better detection in these women. Because 
women with dense breast tissue have a higher risk of breast cancer and are more challenging to 
image using mammography, this is currently a major unmet clinical need in this patient 
population.   
For rheumatoid arthritis, one issue when using these imaging agents in RA detection is 
determining the appropriate patient population for screening. There are several clinical trials 
designed to treat early, even subclinical, patients from high-risk groups. These clinical trials are 
based on genetic factors and autoantibodies that show up in routine blood tests. Although the risk 
of developing RA in these patients is significantly elevated over the normal population, the 
prevalence is still low, so only a fraction of these patients will actually develop the disease. 
Therefore, the biomarkers from blood tests and family history may serve as an excellent ‘pre-
screening’ tool to select the population for an imaging screen. These patients, along with those 
with diffuse symptoms (e.g. undifferentiated arthritis) would be prime candidates for a 
quantitative screen. 
A second issue is differentiation with other forms of arthritis. These include other 
diseases with a similar prevalence, such as ankylosing spondylitis. Although the clinical 
presentation of these diseases are different, differential diagnosis at early stages can be 
challenging. It may be possible that a more quantitative imaging screen, such as the one 
proposed here, will be able to better differentiate these conditions compared to a clinical exam. 
However, this would need to be determined through a controlled clinical trial. Alternatively, 
pairing the current agent, which quantifies inflammation and should have high sensitivity (due to 
the high expression level on activated macrophages) with a second NIR agent that differentiates 
the conditions (improving specificity) would be ideal. This work is continuing in the Thurber lab. 
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As a parallel application in RA, this method may have applicability for the early monitoring of 
treatment response. Typically, once a patients starts a new therapy, the physician will follow up 
within several weeks to months to see if the treatment is effective. For example, the follow up 
visits may determine whether the patient needs to move from a small molecule drug, like 
methotrexate, to a more expensive but powerful biologic. By using the technique described in 
this thesis, the patient could undergo a repeat scan within days to see if the inflammation was 
subsiding at the molecule level, thereby avoiding any additional damage prior to switching 
treatment if required. 
 
Variability in animals and humans 
The technique proposed in this dissertation was tested in rodent models of disease, 
specifically an orthotopic breast cancer model and CAIA model of RA. Continued work is 
needed to see how the pharmacokinetics (absorption and clearance) scale to other species. One of 
the main challenges is accommodating the high patient-to-patient variability. Although the 
contrast is not highly impacted by the amount of absorption, it can be affected if the absorption 
drops below a level necessary for detection above autofluorescence. The variability in absorption 
in other species and the clinic is currently unknown and needs to be tested in ongoing work. 
There is clinical evidence for similar sized hydrophilic molecules, as cited in our publications, 
that the levels will be similar to the amount absorbed in rodents. However, this must be directly 
measured for the molecules employed in this work. If challenges exist, proper formulation may 
be able to overcome and/or improve the amount absorbed in humans and remains a focus in 
ongoing work. 
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Logistics of implementation in the clinic 
In addition to the scientific challenges described above, there are clinical and business 
factors to consider. One significant challenge faced by fluorescent imaging agents is the strong 
precedence for the deeply ingrained imaging modalities like PET, SPECT, CT, MRI etc. in the 
medical industry. The decades-long history of mammography is particularly entrenched in the 
cancer screening field, and the mixed clinical outcomes (successes in early detection weighed 
against the costs of over-diagnosis) have made this a highly controversial topic. There is also 
resistance to change in any large organized system. 
There is no one solution to overcoming these non-scientific (but very real) challenges. 
However, if continued progress in the scientific challenges shows that this is ultimately a more 
successful approach, then several points must be clearly presented to the clinical community to 
help facilitate change.  
First, the approach must clearly show superiority to current methods (e.g. 
mammography). Using an analogy from the pharmaceutical industry, this method would be 
promoted as ‘best-in-class’ versus ‘first-in-class,’ which would then allow it to gain in market 
share for breast cancer screening. To justify this continued development of molecular imaging 
with NIR tomography, for example, it needs to be emphasized that the fundamentals for this 
approach are superior to those used by mammography (and many newer techniques under 
development) and help address many of its limitations. Anatomical imaging will never be able to 
provide molecular information, and cancer is ultimately a molecular disease. This disconnect is a 
major driver of overdiagnosis. Second, it does not use ionizing radiation, so the associated cancer 
risks are much lower. Finally, a significant effort has already developed clinical-grade equipment 
for use with these molecular imaging agents. 
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A second issue is the experience and perception among physicians. Many may be more 
comfortable with a technique that has been used for many years. For practical implementation in 
breast cancer, the method would likely initially be used in women with dense breast tissue, since 
they have limited benefit from mammography (and contrast-enhanced MRI is expensive). The 
convenience of taking a pill versus receiving IV contrast and long scan times for MRI would 
likely cause patients to prefer a NIR tomographic scan. Once more experience was gained in this 
patient population, it would be easier to implement in a wider patient population. While 
experience with any technique is important, this cannot be the driving argument for screening; 
otherwise, physicians would always use the oldest technology available. 
A third factor to consider is the use in other diseases. One of the most widely used NIR 
imaging agents in the clinic is the untargeted dye ICG, developed around WWII. It is generally 
used because it is clinically available rather than because of any particular strengths as an 
imaging agent. It is untargeted, has poor optical properties other than an ideal 
excitation/emission, and clears rapidly through the liver. If some of these agents were FDA 
approved for screening one disease, it would lower the bar to testing in clinical trials for different 
indications. Even if better agents were developed in the future, now the tables would be turned, 
and the orally available probe would be first-in-class.  
The targeted NIR imaging agents provide molecular information about disease sites, but 
the high scattering of NIR light dramatically limits the spatial resolution for deep-tissue imaging. 
This makes it ideal for pairing with other modalities with better spatial resolution – multi-modal 
imaging.  The most promising avenue might be pairing ultrasound with fluorescence molecular 
imaging agents to provide anatomical and molecular information at the same time. Ultrasound 
aligns well with many of the strengths of NIR imaging (both generally low cost, no ionizing 
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radiation, potential for combining with other techniques like optoacoustic imaging, etc.). Similar 
to the strengths of combining PET and SPECT with CT or MRI, the NIR imaging would provide 
molecular information while ultrasound provides anatomical information (and maybe 
physiological info for more complex methods such as Doppler US and photoacoustic imaging). 
In conclusion, in spite of the limitations and drawbacks of this technique, it has 
tremendous promise in the medical industry. The modality itself is continuously evolving with 
great strides being made in increasing spatial resolution and depth of imaging. The ability to non-
invasively detect diseases using a low-risk imaging modality that has the potential of high 
compliance rates can significantly help improve patient outcomes with the early detection of 
diseases.  	 		 	
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